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CHAPTER 1 
1. Introduction 
 
This chapter begins with a discussion of the anatomy and physiology of the lungs, and 
then reviews the transport of drugs (small molecules and macromolecules) from the lungs into 
systemic circulation. It then addresses the applicability of nanoparticles in pulmonary drug 
delivery and covers in detail the different mechanisms available for endocytosis of nanoparticles.  
In addition, this section covers the potential of nanoparticles in clinically relevant diseases such 
as the treatment of metastatic breast cancer with nodal involvement. 
1.1 Anatomy and physiology of the lungs 
 
The lungs have an ancient history of use as a route of delivery for medicines intended for 
systemic or local use. The oldest available record of using lungs for therapeutic purpose dates 
back to 1500BC where Egyptians inhaled medicinal vapors. A brief history of important events 
in pulmonary drug delivery is provided in table 1.  
 
Table 1: History of pulmonary drug delivery of medicines. (Adapted from ref. 5) 
Year Formulation/Device Molecule(s) Disease 
1500BC Egyptians used ‘vapors’ Not known Not known 
1662AD Bennet’s inhalation treatment Not known Tuberculosis 
1802 Potter’s cigarettes Not known Asthma 
1860 Sales-Giron’s portable nebulizer Not known Not known 
1925 Aqueous/nebulizer Insulin Diabetes 
1945 Aqueous/nebulizer Penicillin Lung infections 
1951 Aqueous/nebulizer Isoprenaline Asthma 
1955 Aqueous/nebulizer Hydrocortisone Asthma 
1956 First metered-dose inhaler (MDI) (Freon) Albuterol Asthma 
1960 First dry powder inhaler (DPI) Noradrenaline Asthma 
1988 First multidose DPI Terbutaline Asthma 
1996 First protein aqueous/nebulizer DNAse Cystic fibrosis 
1997 First hydrofluoroalkane MDI Albuterol Asthma 
1998 First antibiotic aqueous/nebulizer Tobramycin Cystic fibrosis 
2006 First protein DPI Insulin Diabetes 
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What makes lungs an important route for drug delivery is the fact that they have a large 
alveolar surface area of more than 100 m2 [1], high solute permeability, limited proteolytic 
activity [2], very thin alveolar epithelium (0.2 µm), and extensive vasculature [3]. The 
respiratory tract can be divided into two regions: (a) the conducting region consisting of nasal 
cavity, pharynx, trachea, bronchi, and bronchioles; and (b) the respiratory region consisting of 
the respiratory bronchioles and alveoli [4]. The trachea divides into two main bronchi which 
further divide into bronchioles and the bifurcations that begin at trachea continue through 23 
stages. The airways undergo about 16-17 bifurcations after which the alveolar region begins 
(figure 1). From figure 2 we can see that the cellular shape and structure changes drastically 
from airways to the alveoli [5].  
 
Figure 1. Schematic of airway branching in the human lung. (Adapted from ref. 5) 
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  Figure 2. Schematic depicting the differences in epithelial cells at different sites in the 
lungs. (Adapted from ref. 5) 
The airway epithelium is made up of at least four cell types including the basal cell 
(progenitor cell), ciliated cell, goblet cell, and the clara cell whereas the alveolar epithelium is 
mainly composed of type I and type II alveolar cells [2], also known as pneumocytes. In the 
airways, the distance covered by the air-blood barrier is about 30-40 µm whereas it decreases to 
approximately 500 nm (60-80 times less as compared to that in the upper airways) in the alveolar 
region [6]. The mucus lining of the airways is about 5-10 µm in thickness [6] which presents a 
formidable barrier for the transport of substances across the upper airways (trachea). In addition 
to the thickness of the airways, the mucociliary escalator in the airways continuously pushes 
particulate matter upwards to be eventually expectorated into the stomach. Particles deposited in 
the upper airways are swept out efficiently whereas those deposited in the deep airways are 
4 
 
eliminated by the mucociliary escalator over a period of about 24 hours [5]. The ciliated 
epithelial cells cover about 30-65% of the airway epithelial cells in the human respiratory tract. 
Each epithelial cell has about 200 cilia of 5-6 µm in length each and a density of 6-8 per µm2. In 
a normal individual the mucociliary clearance rate is about 10mm/min. The number of ciliary 
epithelial cells decreases as the airways become smaller. In the trachea, the ciliary epithelial cells 
constitute 53% of the cell population, whereas in the first airway generation they make up 45% 
of the cell population and in the fifth airway generation they constitute only 15% of the cell 
population [7]. Furthermore, the respiratory tract contains dendritic cells which are present above 
and beneath the basement membrane of epithelial cells [8]. They are present in higher numbers 
in the upper respiratory tract (600-800 per mm2) and their number decreases significantly down 
the respiratory tract and reaches 75 per mm2 in the peripheral lung. Dendritic cells in the 
epithelium of respiratory tract detect, process, and transport foreign antigenic material to the 
local lymph nodes and present them to the naïve T cells present in the paracortical region of the 
lymph nodes [9, 10]. The respiratory tract epithelium also contains γδ T-cells and natural killer 
(NK) cells as part of the innate immunity independent of dendritic cells [8]. Additionally, the 
airways contain B-lymphocytes, eosinophils, mast cells, and basophils which are mainly effector 
cells in response to hypersensitivity reactions [8]. 
As we move further down the respiratory tract, the alveolar region begins after about 17 
bifurcations. There are an estimated 52 billion alveolar epithelial cells [11] and about 500 million 
alveoli in the lungs of a normal human being [12]. On average, each human alveolus has 40 type 
I and 67 type II cells both of which form the alveolar epithelium (figure 3). Though the type II 
cells are more in number, the area covered by type I cells is about 95% of the alveolar 
epithelium. Type I cells have a very thin cell body with long membranous extensions whereas 
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type II cells possess a more cuboidal morphology. Type I alveolar cells perform the function of 
gaseous exchange whereas the function of type II cells is to secrete lung surfactant while also 
acting as progenitor for type I cells [2, 13]. Furthermore, the type II cells also play a  role in ion 
transport and alveolar repair in response to injury [14]. The thickness of lung surfactant layer 
secreted by type II cells is only about 20-80 nm. The pulmonary surfactant is composed of 
phospholipids (80%), neutral lipids (5-10%), and proteins (8-10%) [13]. There are four main 
surfactant proteins SP-A, SP-B, SP-C, and SP-D. The lipophilic SP-B (~8 kD) and SP-C (~4 kD) 
along with the phospholipids take part in reducing the surface tension at the air-liquid interface 
to prevent alveolar collapse. The hydrophilic SP-A (~28-36 kD) and SP-D (~43 kD) play an 
important role in the immune system where they bind to various bacteria, viruses, and allergens. 
By binding to pathogens and particulates, these proteins modulate their interaction with lung 
cells in addition to modulating the inflammatory immune response [15]. Each human alveolus is 
continuously monitored by 12-14 macrophages which try to engulf insoluble particulate matter 
deposited in the alveoli [5, 12]. Particles of diameter less than 260 nm can escape phagocytosis 
by these macrophages whereas those with diameter between 1-3 µm are effectively 
phagocytosed [12]. In addition to macrophages, dendritic cells are present in several lung regions 
including the trachea, bronchi, alveoli, and visceral pleura [16, 17]. A recent study has shown 
convincing evidence that the alveolar macrophages also transport antigens to the lung draining 
lymph nodes [18]. This is a new revelation since it was commonly believed that only dendritic 
cells had migratory capacity to the lymph nodes for antigen transport. Previous studies 
attempting to elucidate the migratory potential of alveolar macrophages to the draining suffered 
serious drawbacks in that they were unable to differentiate between dendritic cells and alveolar 
macrophages [18]. Besides dendritic cells and alveolar macrophages, the alveolar region contains 
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lymphocytes (CD4 cells, CD8 cells, NK cells, and B cells), neutrophils, immunoglobulins (IgG), 
and opsonins (surfactant, C-reactive protein, and fibronectin) [8]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic of a single flattened alveolus (to the right). (Adapted from ref. 2) 
The image on the left represents groups of alveoli; each spherical structure within the alveoli is 
an alveolus. 
1.2 Lymphatics of the lungs 
 
The lymphatic system which consists of lymph vessels and lymphoid organs plays an 
important role in maintaining normal fluid balance in tissues, immune vigilance, and adsorption 
of digested fats. The lymph vessels drain interstitial fluid from tissues and transport the lymph 
towards the venous system. Transport of fluid and macromolecules from tissues proceeds 
unidirectionally through a branching hierarchy in the lymph vessels. The lymphocytes and 
antigen presenting cells enter the lymph capillaries in the periphery and migrate to the lymph 
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nodes via lymphatic vessels [19]. The lymph nodes perform the function of filtering, trapping, 
and processing cellular debris, colloidal material, bacteria, antigens, as well as other substances 
[20].  
The lungs have a well organized system of lymphatic drainage via a superficial 
subpleural lymph plexus and a deep plexus of lymph vessels that accompany the bronchi [21]. 
The lymph vessels of lungs drain through the hilar lymph nodes (also known as 
bronchopulmonary lymph nodes) and from there to the tracheobronchial lymph nodes which 
drain in the bronchomediastinal lymph trunks on each side [21]. The mediastinal trunks usually 
open directly into the junction of the jugular and subclavian veins. However, sometimes the right 
mediastinal trunk ends in the right lymph duct and the left mediastinal trunk in the thoracic duct 
[22]. In such a case the right lymph duct opens into the junction of right subclavian and right 
internal jugular vein and the thoracic duct opens into the junction of left subclavian and left 
internal jugular vein [19]. 
1.3 Pharmacokinetics of drug absorption from the lungs 
The lungs on account of their high absorptive surface area, thin alveolar epithelium, and 
extensive vascularization are well suited for the efficient non-invasive systemic delivery of 
macromolecules and small molecule drugs. In the case of small molecules, the lungs are far more 
permeable for absorption than the gastrointestinal tract [23]. Even for macromolecules, the lungs 
are much more permeable for absorption than any other non-invasive route of entry [2, 24]. 
Many small molecule drugs, peptides, and proteins have very rapid absorption from lungs into 
systemic circulation. Small peptides and proteins show absorption more rapidly from lungs as 
compared to subcutaneous injection.  
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The bioavailability of proteins and peptides from the pulmonary route is 10 to 200 times 
higher as compared to other non invasive routes. In the case of small molecules, lipophilic drugs 
are absorbed extremely quickly where the half life of absorption is approximately 1 to 2 minutes. 
Hydrophilic small molecules show an absorption half life of approximately 65 minutes [25]. 
Table 2 depicts the absorption potential of several hydrophilic and hydrophobic small molecules 
as measured by t1/2 (time taken for absorption of half of the administered dose) after pulmonary 
administration by intratracheal instillation in rats. Small hydrophobic molecules are believed to 
be absorbed rapidly throughout the lungs by way of passive diffusion through the plasma 
membrane. On the other hand small hydrophilic molecules can be absorbed by specific 
transporters or via tight junctions of the epithelial cells [2]. An interesting observation from table 
2 is that erythromycin despite its high log P value shows relatively slower absorption from lungs 
as compared to lipophilic drugs with lower log P values. This can be explained by the fact that 
erythromycin and other macrolides were shown to interact with phospholipids [26-29], therefore 
such interactions with lung lipids may slow absorption of the macrolide class of antibiotics [5] 
and/or drugs with similar lipophilic character. Apart from the strong pulmonary absorption 
potential of small molecule drugs, the lungs contain only a fraction of the metabolizing enzymes 
present in the gut and liver which are encountered in the case of oral delivery [30, 31].  
For small peptides such as insulin it is not clear whether it is absorbed by paracellular 
transport or caveolin mediated endocytosis [2]. However, it is widely believed by scientists in the 
field that paracellular transport is dominant [5]. The deposition in deep lungs of small peptides 
and insulin seems to produce optimal absorption as compared to deposition in the upper airways. 
However, for the high molecular weight (150 kD) immunoglobulins of the IgG class evidence  
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Class Compound Molecular weight (Da) Log P t1/2 (min) k (min
-1) 
Li
pi
d 
In
so
lu
bl
e 
Guanidine 59 -3.56 6.3 0.110 
Urea 60 -2.11 4.7 0.147 
AIB (α-aminobutyric acid) 103 -2.54 57 0.012 
Erythritol 122 -2.29 35 0.020 
N-methylnicotinamide 136 0 50 0.014 
Mannitol 182 -3.1 60 0.012 
p-Aminohippuric acid 194 -0.89 41 0.017 
3-o-methyl-D-glucose 194 -1.69 58.7 0.012 
Decamethonium 258 -4.78 90 0.008 
Sucrose 342 -3.7 84 0.008 
Cyanocobalamin (Vitamin B12) 1355 3.57 190 0.0036 
Heparin 6,000-20,000 4.31 552 0.0013 
Dextran 75,000 - 1670 0.0004 
Li
pi
d 
so
lu
bl
e 
Amitrole 84 -0.86 1.3 0.533 
Isoniazid 137 -0.7 1.9 0.365 
Salicylic acid 138 2.26 1.0 0.693 
Barbital 184 0.65 0.93 0.745 
Sulphaguanidine 218 -1.22 41 0.017 
Pentobarbital 226 2.1 1.0 0.693 
Phenobarbital 232 1.47 1.0 0.693 
Ethambutol 232 -0.41 40 0.017 
Procainamide 235 -0.55 2.3 0.301 
Sulphamethoxypyridazine 280 0.32 1.0 0.693 
Sulphadimethoxine 310 1.63 1.0 0.693 
Hydrocortisone 362.5 1.61 1.0 0.693 
Dexamethasone 392.5 1.83 1.7 0.408 
Tetracycline 444 -1.3 14 0.050 
Erythromycin 734 3.06 6.3 0.110 
Digitoxin 765 1.85 0.3 2.310 
Digoxin 781 1.26 1.0 0.693 
 
 Table 2: The effect of molecular weight and lipophilicity on the rate of absorption of small 
molecules following intratracheal instillation in rats. (Adapted from ref. 22) Note: The t1/2 value 
is the measured time for absorption of 50% of the initial dose; k is the apparent first order rate 
constant; and log P is the octanol-water partition coefficient. The log P values were predicted 
using Syracuse Research Corporation’s KowWin software. 
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indicates that deposition in the larger airways (where there is receptor-mediated 
transcytosis for IgG) is best for absorption [32]. 
The pulmonary delivery of proteins in polymeric nanoparticles provides a sustained 
release in lungs and thereby in the systemic circulation. This approach provides a reduction in 
dosage frequency, and better patient compliance especially for therapeutics such as insulin that 
are traditionally injected intramuscularly [3]. Studies have shown prolonged hypoglycemic effect 
in animals after pulmonary administration of insulin encapsulated in polymeric nanoparticles 
[33, 34]. Moving beyond animal studies, the safety and efficacy of inhaled insulin was evaluated 
in more than 2700 patients with type 1 or type 2 diabetes [35-37]. Several studies have shown 
that inhaled insulin effectively controls blood glucose levels comparable to subcutaneously 
administered fast-acting insulin in type 1 and type 2 diabetics [5]. On the whole, pulmonary 
delivery of drug encapsulated polymeric nanocarriers seems to be very efficient in achieving 
better pharmacokinetics for a wide gamut of therapeutics.  
1.4 Nanoparticles in pulmonary delivery 
Nanoparticles have gained increasing attention for pulmonary drug delivery due to 
several characteristics like targeted deposition, bioadhesion, sustained drug release, and reduced 
dosing frequency [3]. Drug encapsulated polymeric and non-polymeric nanoparticles can be 
administered to the lungs for both systemic and local use [1]. Nanocarriers for pulmonary drug 
delivery include degradable polymeric nanoparticles, liposomes, nanotubes etc. Degradable 
polymeric nanoparticles can be fabricated using natural polymers like albumin, gelatin, alginate, 
collagen, cyclodetrin, chitosan etc. or synthetic polymers such as polyesters (poly (lactic-co-
glycolic) acid, poly (lactic acid), and poly (glycolic acid) etc.,), polyanhydrides (poly(sebacic 
anhydride), poly(adipic anhydride), poly(sebacic acid-co-1,3-bis(p-carboxyphenoxy) propane) 
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etc.,), and polyacrylates (poly(n-propyl acrylate) and poly(n-butyl acrylate)). Synthetic polymers 
have the property to sustain the drug release over a period of days to months whereas natural 
polymers degrade and release the drug in a shorter duration [38]. 
Degradable polymeric nanoparticles have been extensively used in pulmonary delivery of 
several important proteins/peptides and drugs [39]. For deposition of particles successfully in the 
deep lungs the aerodynamic diameter (dae) of the particles should be between 1 to 3 µm. Particles 
with dae greater than 5-10 µm are deposited in the oropharyngeal region and are likely to be 
swallowed [6]. Particles of size less than 100 nm are transported by diffusional displacement and 
deposit efficiently in peripheral airways [40]. Particles of size less than 150 nm have been shown 
to efficiently translocate across the alveolar epithelium and enter systemic circulation [41]. When 
designing particulate systems for lung administration, it is important to note that particles made 
of hygroscopic material or water-soluble particles absorb moisture in the lungs therefore 
changing the particle size, which in turn affects the deposition pattern and efficiency. 
Encapsulating therapeutics in degradable nanoparticles offers protection to the therapeutic from 
peptidases and other degradative milieu in the lungs such as lung surfactant. Moreover, 
encapsulation of therapeutic in nanoparticles allows for the cellular uptake of the nanoparticles 
especially in the case of gene/siRNA delivery. Furthermore, polymeric nanoparticles allow for 
prolonged delivery of the therapeutic thereby reducing the frequency of administering the 
therapeutic which in turn results in patient compliance. All these advantages make biodegradable 
polymeric nanocarriers suitable and necessary for pulmonary drug delivery of a gamut of 
therapeutics. Polymeric nanoparticles can be fabricated using several methods such as 
single/double emulsion method, nanoprecipitation, spray drying, and phase inversion 
nanoencapsulation.  
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1.4.1 Cellular uptake of nanoparticles 
Nanoparticles gain entry into cells by a process called endocytosis wherein the 
nanoparticle interacts with the cell membrane and is then engulfed in the invaginations present at 
the membrane. The invaginations are pinched off of the membrane to form vesicular structures 
known as endosomes. These endosomes then transport the nanoparticle/cargo to other 
intracellular structures. Clathrin-mediated endocytosis and caveolin-mediated endocytosis are the 
two main endocytotic mechanisms for nanoparticle entry into cells [42]. Apart from these two 
major pathways, there are several other endocytotic mechanisms depicted in figure 4. 
 
 
 
 
 
 
Figure 4. Classification of the several different endocytotic mechanisms based on the 
proteins involved in the initiatory process of endocytosis. (Adapted from ref. 42) 
 Clathrin mediated endocytosis (CME) plays crucial role in important physiological 
processes such as nutrient uptake and intercellular communication in all mammalian cells. 
Clathrin-dependent endocytosis is the major mechanism responsible in the internalization of 
macromolecules and plasma membrane constituents in most cell types. Clathrin is a three-leg 
protein that assembles on the cytosolic side of the plasma membrane thereby aiding the 
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deformation of the membrane into a pit of around 150 nm size. Once the cargo is internalized by 
the clathrin coated vesicle, it is transferred to the early endosomes which have an acidic pH (~6). 
These early endosomes then mature into late endosomes which have more acidic pH (~5) as 
compared to early endosomes. The late endosomes fuse with prelysosomal vesicles that contain 
acid hydrolases thereby generating a severe environment that degrades the internalized cargo 
[43].  Therefore, drug delivery systems that are intended for uptake by CME have to be designed 
with the capability to escape the degradative process in the endosomes to be released in the 
cytosol. For instance, polyethyleneimine, a cationic polymer used in the delivery of nucleotides 
has the capability to escape the endosomes by a process termed as the ‘proton-sponge effect’. 
 Apart from CME, caveolae mediated endocytosis is another major pathway for 
endocytosis of materials into cells. Caveolae are flask shaped invaginations of the plasma 
membrane that have a size around 50-100 nm. They are abundantly present in endothelial cells 
constituting about 10-20% of cell surface. The caveolae contain an array of dimeric protein 
caveolin and are also abundant in cholesterol and sphingolipids. Once the particles are 
internalized in the invaginations, the GTPase dynamin causes the fission of caveolae from the 
membrane thereby producing a vesicle which in this case does not contain any degradative 
enzymes unlike clathrin coated vesicles.  Therefore, this pathway may be exploited for purpose 
of drug delivery for sensitive therapeutics such as peptides, proteins, and nucleic acids thereby 
circumventing the lysosomal degradation pathway [43]. Despite the small sizes of clathrin and 
caveolin coated invaginations, a study has demonstrated that for polystyrene nanoparticles of 
size less than 200 nm CME was involved in their internalization. However, surprisingly, for 
larger particles as big as 500 nm size, the caveolae mediated endocytosis was the major 
internalization pathway [44]. The internalization of material via caveolae mediated endocytosis 
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occurs at a much slower rate as compared to that of CME [45]. Both the alveolar epithelial cells 
and the pulmonary capillary endothelial cells have an abundance of caveolar structures [46]. 
Therefore, nanoparticles could potentially exploit this endocytosis mechanism for their 
translocation across the alveolar epithelial cells into systemic circulation.  
1.4.2 Risk assessment of nanoparticles 
 The nanoparticles translocate to distant organs from the lungs and generate adverse 
effects [47]. Apart from systemic effects, they also result in local toxicity to the lungs. However, 
most of the knowledge about pulmonary toxicity of nanoparticles is based on the inhaled 
nanoparticles such as carbon black, diesel particulate matter, titanium dioxide, and silica 
nanoparticles which are considered as ultrafine nanoparticles of size less than 100 nm [48]. 
Nanoparticles have shown to exert a greater inflammatory potential per unit mass as compared to 
particles of larger sizes in rat lungs [49]. Nanoparticles primarily induce toxic effects via 
generation of reactive oxygen species resulting in oxidative stress [50]. 
 It has been shown that inhaled iridium particles may translocate from lungs into 
systemic circulation resulting in severe vascular effects [51, 52]. On the other hand there is 
evidence showing that the toxicity of metallic microparticles was similar to that of metallic 
nanoparticles [53]. This demonstrates that the toxicity may not exclusively be as a result of 
particle size alone. Polymeric nanoparticles have also been tested for pulmonary toxicity. In one 
study, nanoparticles were fabricated using biodegradable polymers poly(butyl)cyanoacrylate and 
poly(hexyl)cyanoacrylate and their toxicity was assessed on human pulmonary epithelial cells. 
With both these nanoparticles, an increase in lactate dehydrogenase (LDH) activity was observed 
[54]. In another study with poly (lactic-co-glycolic) acid (PLGA) nanoparticles, it has been 
shown that they induce much less inflammation as compared to polystyrene nanoparticles of 
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similar size upon administration to lungs [55]. Taken together these results suggest that metallic 
nanoparticles pose a higher risk for pulmonary toxicity and that the nanoparticle size might not 
be the only factor that plays a key role in toxicity. Furthermore, PLGA nanoparticles are more 
amenable for pulmonary delivery on account of their less inflammatory potential and also due to 
the fact that they are completely degradable.       
1.5 Metastatic breast cancer 
 Breast cancer, a complex disease which is highly heterogeneous at both the molecular 
and clinical level is also the leading cause of cancer deaths in women world-wide [56]. Five 
major molecular subtypes of breast cancer namely basal-like, luminal A, luminal B, HER2+/ER-, 
and normal breast like have been identified based on extensive gene expression profiling of 
tumors [57-59]. As a result of the molecular differences, the clinical outcomes and responses to 
treatment are distinct for each subtype with basal-like tumors having the worst prognosis and 
luminal A-type having the best prognosis [60]. As per a recent statistic from breastcancer.org, in 
the year 2011 an estimated 230, 480 new cases of invasive (metastatic) breast cancer and 57,650 
new cases of non-invasive breast cancer were expected to be diagnosed in women in the United 
States [61]. As per statistics from American cancer society, in the year 2012 there would be an 
estimated 226, 870 new cases of breast cancer and an estimated 39,510 deaths resulting from 
breast cancer [62]. The main cause of death from breast cancer is not due to the primary tumor 
but due to metastatic spread of the tumor to distant sites [63]. The heterogeneity of metastatic 
breast cancer is such that it can range from solitary metastatic lesion to widespread metastases 
into multiple organs [64]. Figure 5 depicts breast cancer progression which starts with ductal 
hyperproliferation which then advances into in situ and invasive carcinomas, and finally 
resulting in metastatic spread [56]. It has also been shown in a mouse model that mesenchymal 
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stem cells within the cancer stroma greatly enhance the metastatic spread of breast cancer cells. 
They have been found to do so by releasing a chemokine CCL5 that enhances the motility, 
invasion, and metastasis of the breast cancer cells [65]. Despite advancements in therapy, about 
25-40% of patients with breast cancer develop metastasis which is largely incurable [66]. 
 
Figure 5. A schematic of a hypothetical model of breast tumor progression showing 
ductal changes associated with tumor progression (Adapted from ref .43). 
 Of the various prognostic factors related to breast cancer survival rates, the Nottingham 
study clearly highlights that in addition to tumor size, survival is also significantly dependent on 
the total number of nodes involved in metastasis [67, 68].  The conventional standard in cancer 
staging and determination of prognosis for nearly the past century has involved the removal of 
sentinel and axillary lymph nodes [67-69]. Sentinel lymph nodes are defined as the lymph nodes 
that are first to receive lymph from the vicinity of the primary tumor [68, 69]. Indeed, it was 
discovered way back in the 1830’s that lymphatic drainage from the breast follows into the 
subareolar plexus and ends in the axilla, which paved the way for further investigation of the 
lymphatic network revealing additional lymphatic routes [70]. Approximately one third of breast 
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cancer patients are reported to receive axillary lymph node dissection (ALND) as an initial 
treatment followed by radiation or other adjuvant therapies [67, 68, 71].  
 In the Iowa Women’s Health Study, several important risk factors, including obesity, 
tumor grade and comorbidity are identified as contributors to complications following ALND, 
however, these risk factors are not necessarily present in all cases of reported complications 
following ALND [71, 72].  A major complication that occurs after ALND is lymphedema, which 
has been determined to damage normal lymphatic transport [69, 71, 72].  The volume of 
circulating lymph therefore exceeds the capability of the resected lymphatic network, resulting in 
an accumulation of fibrotic tissue, protein, edema and chronic inflammation within the limb [71, 
72].  Furthermore, the disrupted lymph flow can lead to retrograde lymphatic drainage to the 
liver via the internal mammary chain [70].  The pathology associated with ALND extends to 
reports of decreased quality of life and psychological implications, including anxiety, depression, 
distorted body image and decreased libido in women who have undergone ALND [72, 73].  
Although lymphedema has been reported as both acute and chronic pathology, it is well 
demonstrated in the ALMANAC trial that incidence of lymphedema and associated morbidity is 
significantly reduced 1, 3, 6 and 12 months following sentinel lymph node dissection (SLND) 
versus ALND [72, 73]. Furthermore, women who underwent SLND and later underwent ALND 
reported significantly greater morbidity and disability in the arm as compared to women who 
underwent SLND alone [72, 73].  Taken together, ALND is associated with significant incidence 
of lymphedema related arm morbidities and extends into shoulder and muscular injury and 
clinical presentations including, limited range of motion of the limb, centralized pain consisting 
of tingling, numbness and other sensory defects as well as an increased risk of developing 
infections [67-69, 71-75]. With advancements in diagnostic technology, including the use of 
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lymphoscintigraphy to delineate tumor involvement in lymphatic flow, evidence is emerging that 
suggests that sentinel lymph nodes (SNL) accurately represent the state of axillary lymph node 
involvement in 95.5% of patients with non-SNL evidence of cancer [68]. The removal of 
involved lymph nodes that are determined to receive lymphatic drainage from a tumor using 
radioactive dye lymphoscintigraphy affords conservation of breast tissue and obviates the 
extensive surgical interventions that have previously been widely practiced [67, 69, 74].  
 According to the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 
trial, which focused primarily on the effectiveness of SLND, only a 2% difference was found to 
exist in overall survival of patients that underwent SLND or ALND in SNL-negative 
involvement [69]. This finding was further substantiated in a recent study investigating SLN 
micrometastases, indicating that 38-67% of lymph nodes involved are identified as SLNs and a 
plausible treatments with such tumors is SLND alone and preservation of ALNs [76]. However, 
for patients presenting with multifocal tumors SNLs do not serve as an accurate assessment of 
axillary lymph node (ALN) involvement, as these tumors are likely to involve extensive routes 
of the breast lymphatic network [68, 69, 74]. SLN has emerged as a clinically useful procedure 
that is gaining worldwide notoriety as a standard method of lymph node analysis in node 
negative SNLs identified by lymphoscintigraphy, however optimization for the method of 
identification of SLN involvement and the accuracy with which it predicts ALN involvement is 
still debated [74, 76].  This study has impacted the conventional treatment of breast cancer, 
which typically involved mastectomy, ALND as well as extensive adjuvant therapy: 
chemotherapy, radiation and long term Tamoxifen therapy [67, 69, 74].  Improvement in 
methods used to detect sentinel lymph node involvement has major implications in the 
enhancement of the quality of care for millions of breast cancer patients [69, 74]. However, as an 
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alternative approach, passively targeting the axillary lymph nodes from lungs in cases of node-
positive metastatic breast cancers could offer a solution to the multiple complex pathologies 
associated with ALND. This approach could not only result in effective treatment but also a 
significant improvement in quality of life of the patients.  
1.6 CDF and doxorubicin for metastatic breast cancer treatment 
 Doxorubicin, introduced nearly four decades ago has generally been considered the most 
active drug for metastatic breast cancer. In patients with metastatic breast cancer who have 
received prior alkylating agent chemotherapy, doxorubicin was found to produce excellent 
response rates. At doses between 60 to 75 mg/m2 the response rate was between 25 to 33% [77]. 
Furthermore, it was discovered that at low to moderate doses, doxorubicin and other anti cancer 
agents have the ability to stimulate the immune system against cancer [78]. Doxorubicin when 
administered to mice in moderate doses led to the potentiation of cytotoxic T lymphocyte 
responses (CTL) to syngeneic tumors in addition to increasing the antitumor action of cytotoxic 
macrophages [79]. Difluorinated curcumin (CDF), a curcumin analogue has been shown to 
possess inhibitory activity against several cancer cell lines. Additionally, it acts as a 
chemosensitizer in several cancer cell lines, thereby potentiating the activity of chemotherapeutic 
agents in cancer chemotherapy. Therefore, exploiting the multi faceted abilities of doxorubicin 
and CDF in combination and delivering them to the axillary lymph nodes (by encapsulating the 
drugs in nanoparticles) might offer an alternative for effective treatment in metastatic breast 
cancer with nodal involvement. 
1.7 Hypothesis and specific aims 
Hypothesis 
 Nodal involvement in metastatic breast cancer is well documented. There is 
overwhelming evidence of cancer spread to axillary lymph nodes (ALN) in metastatic breast 
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cancer. Therefore, killing the cancer cells in ALN by way of passively targeting the ALN from 
lungs will be an effective strategy in combating metastatic breast cancer. In light of this idea, I 
hypothesize that CDF encapsulated polymer nanoparticles can be passively targeted to lymph 
nodes via lungs. 
Specific aims 
1. To study the effect of size of polystyrene nanoparticles on their pulmonary 
biodistribution 
 It is well established that nanoparticle size plays an important role in their in vivo 
biodistribution. There is a lot of information available about the effect of nanoparticle size on its 
biodistribution after intravenous administration. However, there are very few studies that 
quantitatively investigate the effect of polymeric nanoparticle size on pulmonary biodistribution 
from a drug delivery perspective. Furthermore, the uptake of nanoparticles occurs by many 
potential mechanisms including phagocytosis, clathrin-mediated endocytosis, caveolin-mediated 
endocytosis, and non-endocytotic pathways. It is hypothesized that these different uptake 
mechanisms may affect the biodistribution of nanoparticles based on their size. Therefore, 
polystyrene nanoparticles of size 50 nm, 100 nm, 250 nm, and 900 nm will be used to investigate 
the effect of nanoparticle size on their pulmonary biodistribution in mice. 
2. To develop an assay to determine the nanoparticle biodistribution and biodegradation in 
vivo 
 Degradable polymeric nanoparticle biodistribution studies are usually performed by 
either physical encapsulation of a fluorescent dye or by means of conjugating the dye with the 
polymer. In this situation, there is a high chance of misinterpreting the results due to the fact that 
fluorescence of the dye alone can be misread as that of the whole nanoparticle. Furthermore, 
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performing biodistribution studies for longer periods of time would not be possible due to the 
fact that the dye would be released over time both from the encapsulated formulation and from 
the conjugate. In such a situation, the nanoparticle is no more associated with the dye and 
therefore the fluorescence of the dye cannot be used as an indicator to track the nanoparticle 
system anymore. Another approach that is used is radiolabeling of the polymer backbone. 
However, this will only give biodistribution data of nanoparticles. The in vivo tissue degradation 
of polymeric nanoparticles has not been investigated yet. Drug release from nanoparticles is 
dependent on diffusion as well as polymer degradation. Therefore, determining the in vivo 
biodistribution of polymeric nanoparticles simultaneously with their in vivo degradation will help 
in designing better drug delivery systems with a highly predictable drug release profile in tissues. 
For this purpose, the biodegradable polymer PLGA will be used to formulate nanoparticles. 
These PLGA nanoparticles will then be administered intravenously in order to simultaneously 
determine their in vivo biodistribution and biodegradation in tissues. 
3. To develop CDF-encapsulated PLGA nanoparticles for use in the treatment of metastatic 
breast cancer 
Difluorinated-curcumin (CDF), an analogue of curcumin has been shown to be a 
chemosensitizer and also potent inhibitor for several types of cancer cells. Since nanoparticles 
are well known to provide special characteristics such as improved bioavailability and half life, 
extended release of the drug, intracellular delivery etc., CDF will be encapsulated in PLGA 
nanoparticles and tested for its activity in cancer cell lines, especially a breast cancer cell line.  
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CHAPTER 2 
2.1 Introduction 
The lungs possess many advantages as an administration pathway including an alveolar 
surface area of around 100 m2 [1], high solute permeability, limited proteolytic activity [2], a 
very thin alveolar epithelium of 0.2 µm, and extensive vasculature [3].  Considerable research 
has been carried out in investigating and improving the pharmacokinetics of several drugs, 
peptides and proteins from the lungs [4-8]. In the field of pulmonary drug delivery, nanoparticles 
have gained increasing attention as they may provide targeted delivery, sustained release, 
reduced dosage frequency, and improved patient compliance [3]. Recently, it has been shown 
that nanoparticles with a maximum size of up to 34 nm are absorbed into the blood stream and 
are also translocated to the regional lymph nodes after administration to lungs [9]. However, the 
size range investigated may be below that of particles that would be well suited for drug delivery 
applications. Therefore, considering the potential of lungs for the purpose of local and systemic 
drug delivery, we investigated the translocation and organ distribution of relatively larger 
nanoparticles through the pulmonary route. To test this, the biodistribution and uptake 
characteristics of polystyrene nanoparticles (PN) of sizes 50 nm, 100 nm, 250 nm, and 900 nm in 
mice, following administration to lungs by pharyngeal aspiration, were evaluated. Polystyrene 
nanoparticles were used as a convenient non-degradable model system due to their high degree 
of monodispersity; a prime importance when evaluating the effect of particle size on 
biodistribution. Since PN are non-degradable, they can be used to quantitatively track the fate of 
PN administered in vivo. 
It has been shown that PN in the range of 250 nm – 3 µm present an optimal size for 
phagocytosis, whereas, those less than 250 nm were shown to be phagocytosed less efficiently 
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[10]. Additionally, particles less than 200 nm in size are extensively internalized via clathrin 
mediated endocytosis [11]. Therefore, nanoparticle sizes in this study were selected based on the 
premise that different uptake mechanisms may possibly lead to varied biodistribution profiles.  
The main objective of this study was to understand the effect of nanoparticle size on their 
uptake and biodistribution from lungs, specifically investigating the lymph deposition. Here, 
with a gel permeation chromatography (GPC)-based detection technique, yielding the 
quantitative concentration of polystyrene present in each tissue from tissue extracts, we 
determine the pulmonary uptake potential and biodistribution of PN.  
2.2 Materials 
PN of sizes 50 nm, 100 nm, 250 nm, and 900 nm were purchased from Polysciences Inc. 
Nanoparticle suspensions of 1% w/v concentration were used. Hematoxylin, eosin Y disodium 
salt, ethyl alcohol (anhydrous), xylene (histological grade), and Permount® were purchased from 
Fisher Scientific. Solvents were of HPLC grade or higher, and were purchased from Fisher 
Scientific. 
2.3 Methods 
2.3.1 Administration of nanoparticles to mice 
Male BALB/c mice weighing between 20-25 g (Charles River Inc.) were used following 
acclimation for one week. Food and water were available to the animals ad libitum. All animal 
procedures adhere to American Veterinarian Medical Association (AVMA) Guidelines, Wayne 
State University Institutional Animal Care and Use Committee (IACUC) approval, in accordance 
with the Office of Laboratory Animal Welfare (OLAW) Public Health Service Policy on 
Humane Care and Use of Laboratory Animals, and Principals of Laboratory Animal Care. All 
studies were performed in animal cohort groups of 6 (n=6). Mice were anaesthetized by 
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inhalation of 2.5% v/v isoflurane and placed on a slant board with the back resting on the board, 
and partially suspended with a rubber band by their incisors. The tongue was held gently in 
extension and a PN suspension was placed in the pharynx region using a Hamilton microliter 
syringe with a 22s gauge needle of length 51 mm. The tongue was continuously held in 
extension until several breaths had elapsed. Once the entire dosage (150 µl) had been 
administered, the mice were returned to their housing and laid on their side. This method has 
been validated in comparison to intratracheal administration and allows for greater lung 
deposition and higher dose-to-dose consistency [12]. To ensure that our results are not dependant 
on the administration method we compared pharyngeal aspiration and intratracheal instillation 
for a single study group. Nanoparticle suspensions were used as provided from Polysciences Inc. 
However, additional biodistribution studies were performed with washed nanoparticles 
suspended in normal saline by sonication. Particle suspensions following the wash were sized 
with dynamic light scattering (DLS) on a 90Plus Particle Size Analyzer (Brookhaven Instrument 
Corporation) and compared to the commercially available suspensions. There was no significant 
difference in the size characterizations of the two suspensions (table 3).   
2.3.2 Harvesting of tissues from mice 
After the administration of nanoparticles, at predetermined intervals of 1, 3, and 5 hours, 
various tissues were harvested. Before performing the terminal surgery, the mice were 
anesthetized by inhalation of 5% v/v isoflurane. The list of tissues harvested is as follows: 
axillary lymph nodes (ALN), brachial lymph nodes (BLN), mesenteric lymph node (MLN), 
cervical lymph nodes (CLN), lungs, liver, stomach, small intestine, kidneys, spleen, blood, brain, 
heart, bronchoalveolar lavage (BAL), and thymus. For collecting the BAL, 0.5 ml of normal 
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saline was injected into the lungs per os and the inflated lungs were gently massaged and the 
rinsate was collected back into the syringe. 
2.3.3 Tissue processing 
Tissue samples were processed and analyzed by a method modified from previously 
described studies [13, 14]. The harvested tissues were physically homogenized using a tissue 
homogenizer. Following homogenization, the tissues were frozen and lyophilized to remove 
water. To each lyophilized tissue vial, chloroform was added and placed on a mixer for 
extraction over 96 hours. Following this, all the tissues were filtered using a 0.2 µm PTFE 
Millipore filter. The filtrate containing the polymer/tissue extracts was frozen at -80˚C overnight 
and lyophilized. Following this, the polymer and/or tissue extracts remain in the vial. To each 
vial, a known volume (0.5 ml or 1 ml) of tetrahydrofuran was added, placed on the mixer for 1 
hour and then filtered into a conical GPC analysis vial using a 0.2 µm syringe filter. To verify 
this method of extraction for PN, three tissues (ALN, heart, spleen) were doped with a known 
amount of PN and processed to extract PN as mentioned above. Upon analysis by GPC, as 
described in section 2.3.4, the extraction yield for PN for the three tissues was 94.5, 98.2, and 
90.9% (table 4). 
2.3.4 Method of analysis 
Analysis of polymer concentration from tissue extracts was performed by GPC (GPC 
Max VE 2001, Viscotek Corporation) equipped with a column bank consisting of three columns 
with size exclusion limits of 4 million, 70,000, and 5,000.  A refractive index (RI) detector (VE 
3580, Viscotek Corporation) was used for polystyrene detection.  The area under the polystyrene 
peak was compared to a standard curve of GPC peaks for polystyrene samples of known 
concentration. This method yields absolute quantitative data and is label-free. The amount of 
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polymer in each tissue is expressed as a percent of administered dose. As this is a quantitative 
method, mass balance was analyzed for all study groups and the quantity of PN residing in the 
lung tissue at each time point is presented. 
2.3.5 Tissue histology 
Five hours after administering the particles by pharyngeal aspiration, the mice were 
sacrificed and the harvested tissues (lungs and lymph nodes) were fixed with 4% 
paraformaldehyde overnight at 4°C. The lung sections were cryosectioned on a cryotome 
(Cryotome FSE, Thermo Scientific) into 10 μm-thick sections, which were then stained with 
standard hematoxylin and eosin (H&E) staining (Harris hematoxylin for 3 min followed by 
running tap water for 1 min, eosin Y for 5 min, 70% ethanol for 1 min, 95% ethanol for 1 min, 
100% ethanol for 1 min, two rinses in 100% Xylene for 1 min each) and cover slip mounted. The 
stained lung and lymph node tissues were then observed under inverted bright field microscopy 
(Olympus 1x71, DP70). 
2.3.6 Transmission electron microscopy 
Portions of tissues harvested for histology were also collected for transmission electron 
microscopy (TEM). Tissues were dissected down to 1–2 mm3 and fixed in 2% paraformaldeyde, 
1.25% glutaraldehyde, 0.2% sucrose and 25mM HEPES buffer in 0.12M sodium cacodylate 
TEM buffer at 4oC for 4 hours.  Tissues were then washed in 0.12M sodium cacodylate, 
gradually going to room temperature. A secondary fix in 3% glutaraldehyde and 4% tannic acid 
(lipid mordant) in sodium cacodylate at 37 oC for 1 hour, was performed and rinsed with 0.12M 
sodium cacodylate. Osmium tetroxide and 2% sodium cacodylate were used as post-fixative 
stains. For application of a non electron-dense staining, samples were stained en block with 2% 
uranyl acetate followed by dehydrating tissues in graded ethanol series of 10 minutes each. Fixed 
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tissues were transfer to conical Beem capsules (Electron Microscopy Sciences; Hatfield, PA). 
Propylene oxide was added quickly and enclosed with the tissue for 2 hours. Finally, Embed 812 
was added in gradual ratios for 2 hours. Samples were cured at 55oC for 2 or 3 days. Tissues 
were ultrathin sectioned using a microtome Diatome with a diamond knife, transferred to 
Formvar film copper grids, and post-stained with NaOH-treated 0.03% lead citrate for 5 minutes. 
The stained tissues were then observed under a Zeiss EM-900 TEM at 50Kv. 
2.3.7 Statistical analysis 
Data are expressed as mean ± SEM with cohort sizes of 6. Statistical analysis was 
performed using one-way ANOVA followed up by Tukey’s test with OriginPro® software. The 
differences were defined statistically significant at p<0.05. 
2.4 Results 
2.4.1 Effect of size on the total uptake of PN 
Total uptake for all PN sizes at 1, 3 and 5 hours is shown in figure 6.  At 1 hour, the total 
uptake for 50 nm (5.2%) and 100 nm (6.2%) PN is low, and is higher for 250 nm and 900 nm at 
14.8% and 14.7%, respectively. At the 3 hour time point, we see a reversal in trend where the 50 
nm PN has the highest total uptake (24.4%) and an increase in PN size leads to a decrease in total 
uptake. At this time point, the total uptake for 100 nm is 11.3% and for 250 nm is 13.1%, further 
decreasing to 4.8% for the 900 nm PN. A similar trend can be seen at the 5-hour time point 
where the highest total uptake is for 50 nm PN at 20.9% and the lowest is for 900 nm PN at 
7.5%. At this time point, the total uptake for 100 nm and 250 nm PN is 15.3% and 12.4%, 
respectively. Inset in figure 6 is a representative histology image of the lung 5 hours after 50 nm 
PN administration. It can be noted that there is minimal infiltration and alveoli are intact. While 
it is not possible to see discrete particles at the image magnification, no aggregated clusters of 
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nanoparticles were seen either. When the lung tissue was further investigated with TEM, discrete 
PN are seen without the presence of aggregates (figure 7). Both larger PN and small PN 
(representative images for 900 nm and 50 nm PN shown in figure 7) were internalized from the 
alveolar space into the interalveolar septum without observed disruption to the epithelial cell 
layer.  
2.4.2 Effect of size on the biodistribution of PN 
The biodistribution of PN of different sizes (50 nm, 100 nm, 250 nm, and 900 nm) at time 
points of 1, 3, and 5 hours is presented in figures 8 – 10. The distribution of PN in tissues is 
represented as % of the total administered dose. In this study, the amount of PN in lymph nodes 
(LN) is the cumulative amount of PN detected in each of the tissues including axillary, brachial, 
cervical, mesenteric lymph nodes, and thymus (a primary lymphoid organ). The highest 
deposition of nanoparticles was in the lymph nodes and the lymph node of highest deposition 
was the axillary node for each of the sizes studied. LN deposition is discussed in further detail in 
the subsequent section.  
      In the liver, the primary reticuloendothelial system (RES) organ, there is minimal 
presence of PN across all time points and sizes. The highest level of liver accumulation is 1.1% 
of the dose for 50 nm at hour 3. For all sizes, no PN were detected in the liver at 1 hour post-
administration.   
Further, the larger 900 nm PN were not found in the liver during any of the time points 
tested. In the first hour after pulmonary administration the only organ to have significant 
accumulation outside of the LN is the spleen. In spleen, we see a general trend of increasing PN 
accumulation with an increase in size, the highest being 2.2% for 900 nm PN. Distribution to all 
other tissue compartments was minimal (<1%) including the central blood compartment.   
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However, by hours 3 and 5 post-pulmonary administration, a significant amount of 50 nm 
PN (3.4% and 3.1%, respectively) was detected in the blood compartment.  Blood distribution 
was low for all other sizes with the highest being 1.3%. At these time points, PN distribution was 
highest in the LN followed by heart and spleen, with very low amounts detected in other tissues.  
This was true for all sizes except for 50 nm where more PN were present in the blood than 
spleen. There is also a general inverse relationship to PN size across all tissues with smaller PN 
having higher deposition than larger PN.  
To ensure that the uptake and biodistribution results reported here were not an artifact of the 
nanoparticle suspension media, we tested 900 nm PN after a series of washes and re-suspension 
in sterile saline. Sizing data for the two suspensions can be found in table 3. The uptake and LN 
distribution of the washed nanoparticles (biodistribution shown in figure 11) were similar to the 
manufacturer suspension without statistical differences. However, the washed particles did have 
significantly less distribution to the heart and spleen. Additionally, for a single study group (50 
nm at 5 hours), intratracheal installation was compared to pharyngeal aspiration to identify any 
possible dependencies of our results on the method of administration. Comparison of the 
biodistribution following the two methods is shown in figure 12. The pattern of tissue 
distribution remained the same with the LN having the highest deposition; however, both the 
uptake and the LN distribution were significantly less for the intratracheal administration as 
discussed in further detail in section 2.5. 
2.4.3 Lymph node distribution of PN 
PN were deposited in greater amounts in the lymph nodes as compared to other tissues 
for all PN sizes and time points as can be seen in figures 8 – 10. The amount of PN deposited in 
the lymph nodes was highest for 50 nm size at 5 hours (12.3% of dose). The 100 nm PN show a 
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trend of increasing lymph deposition with time ranging from 3.6% to 6.9% over the period of 5 
hours. For the 250 nm size, there is no statistically significant difference in the amount of PN 
deposited in the lymph nodes at the three time points where the amount of lymph node 
deposition of PN ranges from 6.5 to 8.0% of dose. For the 900 nm PN, the lymph deposition is 
the highest at 1 hour (6.2%).  Similar to the results of total PN uptake, the PN distribution to the 
lymph is highest for the larger PN in the first hour, but for 3 and 5 hours the trend reverses 
resulting in an inverse relationship with size (smaller PN have highest LN distribution). 
However, when the lymphatic distribution of PN is normalized for the amount of PN 
uptake (i.e. the amount of PN in the lymph nodes calculated as a percentage of the total absorbed 
PN from the lungs) further information on LN specificity and PN size relationship is gained. 
From the normalized lymphatic distribution (figure 13), the 1 hour time point displays a general 
decrease in the percentage of absorbed PN depositing in LN with increased PN size though no 
statistical differences exist. However, at the 3-hour time point we see a general trend of 
increasing percentage of absorbed PN depositing in lymph nodes for each increase in PN size 
with no statistical significance at this time point. Furthermore, at this time point the 900 nm PN 
has a normalized lymph deposition of 50.3% compared to 33.4% for the 50 nm PN. The 5 hour 
normalized LN distribution reveals that no trend and no significant differences exist among all 
NP sizes. 
To further investigate the LN specificity beyond the normalized data, the amount of PN 
per gram of tissue was plotted (figure 14) based on the wet tissue weight directly following 
tissue harvesting. For 50 nm PN at 5 hours, the amount of PN per gram of tissue in LN (3 mg/g) 
is more than 4-fold higher as compared to that in spleen (0.7 mg/g), which is the organ with the 
next highest distribution of 50 nm PN. Similarly, the amount of PN per gram of tissue in LN 
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when compared to liver and spleen combined together is 3 times higher for 100 nm, more than 4 
times higher for 250 nm, and ~4 times higher for 900 nm PN (figure 14). Similar results are 
observed at the 1 hour and 3 hour time points where the amount of PN deposition in LN is 
multiple fold higher as compared to the liver and spleen (figure 14).  
Since the ALN was the tissue of highest PN distribution among the lymph nodes tested, 
ALN tissue was histologically examined and a representative image of ALN with 250 nm PN is 
shown (figure 15). It can be seen that a cluster of PN is present in the ALN. The PN cluster is an 
irregularly shaped aggregate distinct from that of the relatively larger, and round nuclei of the 
ALN. The PN cluster becomes more obvious in the magnified image inset in figure 15. 
2.5 Discussion 
In this work, we investigated the uptake and tissue distribution of 50 nm, 100 nm, 250 
nm, and 900 nm PN following pulmonary administration. We observed that PN of the stated 
sizes distribute from the lungs to LN in relatively large amounts and to other major organs to a 
lesser extent including little distribution to RES organs. The relatively rapid and high uptake of 
the model PN to LN, in addition to a high LN specificity, suggests potential for LN-directed 
pulmonary drug delivery.   
The total translocation of PN out of the lungs was found to be significant with as much as 
20.9% in as little as 5 hours for the 50 nm PN (figure 6). The translocation of PN from the lungs 
to extrapulmonary organs is in accordance with the observations made by Sarlo et al., where they 
reported the translocation of fluorescently labeled PN of sizes 20, 100, and 1,000 nm from the 
lungs into various organs including liver, spleen, heart, brain, and kidneys [15]. In their study, 
rats were subjected to an acute exposure or a repeated exposure of fluorescently labeled PN to 
the lungs followed by semi-quantitative analysis of fluorescent intensities in excised organs. In 
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all cases (the quantitative results presented here and the semi-quantitative observations in the 
paper by Sarlo et al.) the smallest size PN (50 nm and 20 nm, respectively) had the highest 
extrapulmonary translocation. In addition, at the early time point of 1 hour, both studies 
demonstrate lower uptake for the small PN size compared to larger PN sizes. Size-dependant 
translocation kinetics, where smaller PN have a relatively slower initial translocation, but higher 
overall translocation compared to larger PN, may be a result of different internalization 
pathways. Our investigation of lung tissue with TEM demonstrated PN internalization from the 
alveolar space into the interalveolar septum (figure 7). Uptake mechanisms are not directly 
evident from these images, but are an area of current investigation. However, it is clear that PN 
of all sizes are being internalized from the lung alveoli as indicated from our quantitative uptake 
and biodistribution analysis. 
Following translocation from the lung, the tissue of highest PN deposition is the LN. The 
amount of 50 nm PN in LN is 12.3% at 5 hours, which is more than half the total uptake 
(20.9%). This is a particularly significant amount of lymph node translocation of PN in a short 
time frame of 5 hours. Histological examination of the ALN resulted in discrete irregular 
aggregates of PN that are distinct from the surrounding nuclei as represented in figure 15. The 
irregular aggregated pattern does not resemble any immune cells of the lymph nodes or any other 
structure belonging to lymph nodes. Therefore, it can be said that the aggregates we observe in 
the ALN is likely to be a cluster of PN. Further, we postulate that the PN transit to the LN by 
route of macrophage or dendritic cell transit due to the aggregated nature of the PN in the ALN.  
Previously, it was shown that polymer nanoparticles of different sizes and surface 
properties passively deposit in the lymph nodes (popliteal, iliac, inguinal, and renal lymph nodes) 
when administered under the dorsal surface of the left hind footpad in rats [16]. However, 
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subcutaneous or intramuscular injection routes of administration have not been shown to 
effectively target nanoparticles to the regional lymph nodes of the thoracic cavity and neck (i.e. 
ALN, BLN, and CLN), which play a critical role in many diseases including breast cancer, lung 
cancer, and lymphadenopathies. Oussoren and Storm have shown that liposomes of 100 nm size 
do deposit in ALN and BLN, but at a very low amount (of less than 2% of injected dose/g of 
tissue) following subcutaneous administration [17]. In contrast to this, we see a very high amount 
of PN depositing to the ALN, BLN and CLN after pulmonary administration, ranging from 90-
230% of administered dose/g of tissue (when calculated in the same manner as Oussoren and 
Storm). This suggests that pulmonary administration may be a preferred route to effectively 
deposit nanoparticles in the ALN and BLN.    
An interesting observation from the LN deposition of PN is that, though the 50nm                                                                       
PN had the highest LN deposition (figure 10), the 900 nm PN had a greater percent of the 
absorbed PN depositing in LN (figure 13). This is an important observation indicating the 
greater fraction of the absorbed PN accumulating in the LN presents a potential for effective LN 
targeting, thereby significantly reducing the possibility of systemic side effects. Moreover, PN of 
all the sizes tested have a higher propensity to deposit in the LN as compared to other tissues.  
The specificity of PN for LN over major organs, especially the RES organs (liver and 
spleen), is a remarkable result. From figure 14, at the 5 hour time point the amount of PN in LN 
is in the range of 1,140 – 3,027 µg /g of tissue with the highest deposition being for the 50 nm 
size, and lowest for the 900 nm size. Considering the small size and weight of the LN, this is a 
significant amount of deposition and may indicate localized therapeutic potential for 
biodegradable nanocarriers of similar properties to the model PN. Therefore, the significant 
amount of uptake from lungs in the short time period of 5 hours in addition to the high 
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propensity of PN distribution to the LN supports the potential of nanoparticulate pulmonary drug 
delivery systems for systemic and lymph-targeted therapies. 
The liver, spleen, and lungs constitute the RES, which is responsible in removing foreign 
substances from blood circulation following opsonization [18]. When administered 
intravenously, a great majority of polymer nanoparticles accumulate in the liver and spleen as a 
result of RES sequestration [15, 19-23]. Evasion of RES clearance has become a large area of 
interest in the drug delivery field resulting in the prevalence of ‘stealth’, PEGylated carrier 
systems. It has been widely reported that a great proportion of polymeric and non-polymeric 
nanoparticles are sequestered by the RES within a time frame of minutes to less than an hour 
after intravenous administration [24-26]. However, when administered to the lungs, the PN are 
deposited in small amounts (of less than 2% of administered dose) in the liver and spleen. This 
result is in accordance with the observation by Sarlo et al. (15), where less than 1% of the 
recovered dose of fluorescently labeled PN was deposited in the liver and spleen following 
administration to lungs by pharyngeal aspiration. The negligible amounts of PN deposited in the 
liver and spleen is of particular interest as it indicates the pulmonary route as another potential 
systemic delivery mechanism to evade RES. 
PN that do distribute to the RES organs are found mostly in the spleen and the 
biodistribution pattern of spleen mimics the general trend of biodistribution in LN. At the 1-hour 
time point in spleen, we see a general trend of increase in the amount of PN with increasing size 
as seen in LN (figure 8). However, at 3 and 5 hours, we see the amount of PN in spleen 
decreases with an increase in size, again similar to LN at these time points (figures 9 and 10). 
We speculate that PN transit from the lung to LN, and then through the lymphatic system to the 
spleen.  This is further substantiated by the observation of PN in higher amounts in the spleen 
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than liver.  If PN transit to the spleen were to occur through the blood circulation, we would 
expect to see deposition in both the liver and spleen by RES sequestration. 
In order to further verify the observed biodistribution data, 50 nm PN uptake and 
distribution studies (the study group with highest total uptake and lymph distribution) were 
repeated under additional study conditions. To ensure that the suspension medium was not a 
factor influencing total uptake, PN were washed several times, lyophilized and resuspended by 
probe and bath sonication in sterile, normal saline. Size characterizations of the washed and 
commercial suspensions by DLS were not statistically different (table 3). Uptake and 
biodistribution results from the washed nanoparticle study group did not show any significant 
difference to the studies discussed above (figure 11).  Additionally, we repeated studies using 
intratracheal installation despite pharyngeal aspiration already being validated by other labs [12, 
15], and found very similar results, but with a slight decrease in the total uptake, which was not 
statistically significant (figure 12).  This slight decrease in uptake may be due to non-even lung 
deposition with intratracheal administration [12]. No differences in biodistribution were 
observed. Histology of the lung following PN administration demonstrates that the alveolar wall 
was of normal thickness and there was no evidence of alveolar collapse. In the lung image, there 
appears to be little or no severe cell infiltration and inflammation, suggesting that the PN 
administration caused no severe acute damage to the lungs. In contrast, the intratracheal 
instillation technique of administering the payload to lungs invokes severe cell infiltration and 
inflammation due to invasiveness of the technique [27]. Therefore, we feel the pharyngeal 
aspiration technique is more suitable for studying the biodistribution of nanoparticles from lungs. 
Recently, the method has gained attention as a more suitable technique for studying chemically 
induced diseases such as asthma [28].  
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The quantitative nature of the GPC assay used allowed us to determine mass balance for 
all study groups. The mass balance of PN ranges from 80-90% of the administered dose for all 
sizes at 1 hour. However, it decreases with time for all sizes (figure 16). We attribute this 
decrease in mass balance to the possible redistribution of PN to tissues like muscle, bone, 
adipose tissue, urine, etc.: tissues that were not collected in this study. In the discussion above we 
took the conservative approach of only considering the particles detected in tissues when 
calculating uptake. However, our mass balance indicates that the potential uptake may actually 
be higher. Figure 17 represents the amount of PN in the lungs at all time points for all PN sizes. 
Except for the 900 nm PN, there is a general trend of decrease in the PN amounts in lungs with 
time for all other PN (figure 17). 
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Figure 6.  Extrapulmonary uptake of 50, 100, 250 and 900 nm PN at 1, 3 and 5 hours 
following pulmonary administration as a % of dose. * p<0.05 (n=6; mean ± SEM). Inset; 
histology of lungs after administration of 50 nm PN (630X magnification). 
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Figure 7. TEM images of lungs after 900 nm (a) and 50 nm (b) PN administration. AS, 
alveolar space; B, red blood cell; EC, epithelial cell layer; M, mitochondria; *, PN. Scale bars 
are 2.5 µm (a) and 600 nm (b). 
 
  Figure 8. PN biodistribution 1-hour after pulmonary administration as a % of dose. LN, 
Lymph nodes; *, p<0.05 when compared to every tissue among each size; #, p<0.05 when 
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comparing the two tissues represented by this symbol (n=6; mean±SEM). Inset; percent PN 
distribution among various LN. ALN, axillary lymph nodes; BLN, brachial lymph nodes; CLN, 
cervical lymph nodes. 
           
  Figure 9. PN biodistribution 3-hours after pulmonary administration as a % of dose. LN-
Lymph nodes; *, p<0.05 when compared to every tissue among each size; †, p<0.05 when 
compared to every tissue except for heart, #, p<0.05 when compared to every tissue except for 
heart and blood. §, p<0.05 between the two tissues represented by this symbol (n=6; mean ± 
SEM). Inset; percent PN distribution among various LN. ALN, axillary lymph nodes; BLN, 
brachial lymph nodes; CLN, cervical lymph nodes. 
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  Figure 10. PN biodistribution 5-hours after pulmonary administration as a % of dose. LN-
Lymph nodes; *,p<0.05 when compared to every tissue among each size (n=6; mean ± SEM). 
Inset; percent PN distribution among various LN. ALN, axillary lymph nodes; BLN, brachial 
lymph nodes; CLN, cervical lymph nodes. 
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Figure 11. Biodistribution of PN (normal and washed) of 900 nm size 1 hour after 
administration to the lungs. LN, lymph nodes; *, p<0.05 between the two data sets (n=6; 
mean±SEM).  
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Figure 12. Comparison of the biodistribution of 50 nm PN 5 hours after administration 
by intratracheal instillation and pharyngeal aspiration. LN, lymph nodes; *, p<0.05 between the 
two data sets (n=6; mean±SEM).  
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Figure 13. Normalized lymph node deposition of PN 1, 3, and 5 hours after pulmonary 
administration as a % of uptake (n=6; mean ± SEM). 
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Figure 14. Lymph node (LN) specificity of PN 1, 3, and 5 hours after pulmonary 
administration. *, p<0.05 when compared to the other two sets of tissues (non-uptake and others) 
among each size. Amount of PN in LN is represented as µg/g of tissue compared to non-uptake 
(lung, lung rinse, GI) and others (all others including liver, spleen and heart) (n=6; mean ± 
SEM). Note: Non-uptake includes the nanoparticles deposited in lungs and GIT.      
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Figure 15. Histological image of the axillary lymph node (ALN) 5 hours after pulmonary 
administration of 250 nm PN (630X magnification). Inset; digital magnification of the cluster of 
PN (arrow) in the ALN. PN cluster is distinct from the bigger and more regular shaped nuclei 
seen throughout the image. 
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Figure 16. Mass balance for all study sets (n=6; mean ± SEM). 
 
 
 
 
 
 
 
 
         
 
Figure 17. Amount of PN present in the lungs at all time points. *, p<0.05 between the 
indicated time points (n=6; mean ± SEM). 
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Table 3: Size of polystyrene nanoparticles before and after washing with deionized 
water. 
 
 
 
 
Table 4: Recovery of PN from doped tissues after processing 
2.6 Conclusions 
This study illustrates the potential of nanoparticles administered to the lungs for systemic 
use in general and lymph related therapies in particular. Though clear differences in 
biodistribution and uptake were observed based on the nanoparticle size, other physiochemical 
parameters also affect the biodistribution, but are not in the scope of this work. Furthermore, 
when designing nanoparticles for pulmonary administration, the potential of toxicity to the lungs 
needs to be taken into consideration.  
We observed a higher deposition of nanoparticles in the regional lymph nodes as compared to 
other major tissues. The importance of this result is augmented by the relatively rapid transit 
following lung administration (≤5 hours).  Further research in this area is needed to exploit the 
potential of nanoparticles delivered via oral inhalation for vaccines or in the treatment of an array 
of lymph related disorders. 
 
Parameters Before washing After washing 
Size (nm) 833.3±31 788.2±89 
PDI 0.102±0.039 0.052±0.03 
Tissue Amount of PN added (mg) 
Amount 
recovered (mg) % Recovery 
ALN 0.55 0.52 94.5 
Heart 0.55 0.54 98.2 
Spleen 0.55 0.50 90.9 
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CHAPTER 3 
3.1 Introduction  
 Nanoparticles hold promise as drug delivery devices due to their ability to stabilize 
and/or protect the encapsulated drug, control release of drugs, and enable/enhance intracellular 
uptake. In addition, polymeric nanoparticles can be fabricated from polymers that are 
biocompatible and have degradation products that can be easily cleared or may even consist of 
natural byproducts [1, 2]. The ability of nanoparticles to transit across cellular membrane barriers 
and effectively release the cargo has been demonstrated for various drugs including nucleic acids 
and proteins [3]. Further, nanoparticle delivery systems may reduce side-effects by improving 
drug delivery efficiency to affected areas (targeting) and by sustaining pharmacological effects 
[4]. These numerous drug delivery advantages of nanoparticles emanate, in part, from the diverse 
physical, chemical, and biological properties that can be achieved [5]. PLGA is a particularly 
important polymer for use in nanoencapsulation due to its biodegradability by hydrolysis and 
biocompatibility. Already approved by the FDA for use in some drug delivery applications, 
PLGA degrades into lactic and glycolic acid, byproducts of metabolic processes [6]. 
          The particular method of nanoparticle fabrication and encapsulation is chosen based on the 
type of drug used, desired route of administration and the preferred nanoparticle properties. For 
polymeric nanoparticles, solvent evaporation, solvent diffusion (or removal), and 
nanoprecipitation are commonly utilized techniques [7]. All of these techniques often suffer from 
the problem of low encapsulation efficiency of hydrophilic molecules due to rapid partitioning of 
the drug into the external aqueous phase. This problem has been overcome by modification of 
these nanoparticle fabrication methods [8]. Additionally, novel encapsulation methods to 
62 
 
improving encapsulation efficiency of hydrophilic drugs (including proteins) have been 
developed.  
          One such method, phase inversion nanoencapsulation (PIN), can produce nanoparticles in 
a one-step process without the use of an aqueous phase or the need for stirring and/or 
temperature control. Several variables, including concentration of polymer, viscosity of the 
polymer solution, miscibility of solvent/non-solvent, and volumetric ratio of solvent/non-solvent 
can be used to alter nanoparticle properties including size when created by PIN [9].  
Furthermore, this method of fabrication is especially advantageous for protein encapsulation.  
Using the PIN method, insulin has been successfully encapsulated in polymeric nanoparticles, 
shown to release insulin in vivo in the biologically active form [10] and has been successful as an 
oral formulation in a diabetic rat model [11]. Using this method, Mathiowitz et. al. were able to 
obtain a mean particle size of 96.7 nm with the copolymer poly(fumaric-co-sebacic anhydride) 
[10]. However, this method of nanoparticle fabrication can be applied to a range of polymeric 
materials including PLGA. Therefore, we chose this method with an aim of fabricating PLGA 
nanoparticles of the smallest possible size.  
          The use of polymeric surfactants such as polyvinyl alcohol, pluronic F-68 or others is 
common in the conventional nanoparticle fabrication methods such as emulsion method and 
nanoprecipitation. Surfactants are commonly used in nanoparticle fabrication to reduce 
interfacial tension thereby stabilizing the nanoparticle suspension, reducing nanoparticle size and 
preventing aggregation. The effect of surfactant concentration on nanoparticle size is well 
documented in the conventional single and double emulsion methods [12, 13]. Whereas in the 
case of the PIN method, to the best of our knowledge there have been no published reports 
studying the effect of surfactants on particle size and other physiochemical properties. Therefore, 
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we carried out this study investigating the effect of non-ionic surfactant HLB (hydrophile-
lipophile balance) on nanoparticle characteristics with a particular objective of obtaining the 
smallest possible nanoparticle size.  We investigated Span 85 (HLB 1.8), Merpol A (HLB 6), 
Polyoxyethylene sorbitol hexaoleate (PSH) (HLB 10), and Tween 80 (HLB 15) effects on the 
physical properties of the nanoparticles including size, zeta potential, surface morphology and 
thermal properties on PLGA nanoparticles fabricated with PIN. Additionally, we investigated the 
effect of surfactant concentration.  
From our studies discussed in chapter 2 (specific aim 1) we have seen that nanoparticles 
with the smallest particle size had the highest potential of translocation out of the lungs as well 
as deposition in the lymph nodes. However, the nanoparticles used in that study were non 
degradable and they were only used as a model system as emphasized and explained in further 
detail in chapter 2. For the purposes of drug delivery, a degradable nanoparticle system is desired 
which is both biocompatible and non-toxic. PLGA is one such polymer that has been extensively 
used in the formulation of drug loaded nanoparticles. Therefore, we envisioned the use of PLGA 
polymer to encapsulate a model drug for its pulmonary delivery. This chapter discusses the 
several approaches that have been employed in order to obtain PLGA nanoparticles of different 
sizes for further use in the study of their in vitro and most importantly in vivo tissue degradation 
characteristics which is a focus of chapter 4 (specific aim 2). This chapter therefore is a part of 
specific aim 2 wherein PLGA nanoparticles are fabricated for exploration of their in vivo tissue 
degradation characteristics. 
3.2 Materials 
 PLGA (Resomer RG 502, 50:50) with an inherent viscosity of 0.16-0.24 dL/g was 
obtained from Boehringer Ingelheim (Germany). Span 85, Merpol A, Tween 80 and all solvents 
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including dichloromethane and petroleum ether were of analytical grade (Fisher Scientific, 
USA). Polyoxyethylene sorbitol hexaoleate (PSH), polyvinyl alcohol (PVA) were purchased 
from Sigma Aldrich, USA. 
3.3 Methods 
3.3.1 Nanoparticle fabrication by PIN method 
 Nanoparticles were formulated using the PIN method as describe elsewhere [10].  
Briefly, a 4% w/v PLGA solution in dichloromethane (solvent phase) was prepared. The 
surfactants were added to the solvent phase. This polymer solution was added quickly to a bath 
of petroleum ether (non-solvent phase) under stirring at 1000 rpm using an overhead stirrer in a 
solvent:non-solvent ratio of 1:100 resulting in the rapid formation of solid nanoparticles. The 
dispersion was then positive-pressure filtered through a membrane filter of pore size 0.20 µm 
(Millipore). The nanoparticles were collected, lyophilized and stored at -20˚C until further use 
and characterization. Formulations were labeled S1 through S16 and each formulation was 
replicated thrice to account for inter batch variability. The numbers in the notation indicate the 
surfactant and concentration used as detailed in table 5.  Formulation C was prepared without the 
use of surfactant as a comparative control. 
3.3.2 Nanoparticle fabrication by emulsion method and nanoprecipitation method 
 Nanoprecipitation method. For the 200nm size nanoparticles, 0.9% of PLGA solution 
in acetone was added drop wise to an aqueous solution of 1% PVA at a stirring speed of 800 rpm 
overnight [14]. The nanoparticles were centrifuged at 40,000 x g for 1 hour and were then 
washed with 30 ml deionized water thrice following which they were resuspended in 15 ml of 
deionized water, frozen and lyophilized.  
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Emulsion method. For the 500 nm size nanoparticles a previously used method was 
slightly modified from a previously published method [15]. Briefly, 2 ml of 5% PLGA solution 
in dichloromethane was added to 30ml of 0.5% PVA and sonicated at 30 watt output for 10 
minutes on an ice bath. This preparation was then added to 100 ml of deionized water under 
magnetic stirring at 600 rpm overnight. The preparation was centrifuged at 40,000 x g to collect 
the nanoparticles following which the nanoparticles were washed thrice in 30 ml deionized 
water. After this step, the nanoparticles were resuspended in 15 ml of deionized water, frozen, 
and lyophilized. The nanoparticles were resuspended in 0.9% saline before administration for 
animal studies. 
3.3.3 Size Analysis 
 The formulations made by the PIN method were reconstituted with 1% Pluronic F-127 
solution to make 0.1% w/v dispersion and sonicated for 30-60 seconds in a bath sonicator to 
disperse the nanoparticles. The dispersion was then subject to size analysis on a 90Plus Particle 
Size Analyzer (Brookhaven Instrument Corporation).  Mean values following 10 runs for each 
formulation were recorded. 
The nanoparticle formulations made by the emulsion method and the nanoprecipitation 
method were reconstituted with 0.5% PVA solution to make a dispersions of 0.1% w/v 
concentration which were sonicated for about 30-60 seconds in a bath sonicator to disperse the 
nanoparticles. The dispersions were then subject to size analysis on a 90Plus Particle Size 
Analyzer (Brookhaven Instrument Corporation). 
3.3.4 Scanning electron microscopy 
 A small amount of the lyophilized formulation was mounted on a carbon adhesive tape 
and sputter-coated with gold using 70 mA current for 25 seconds. Images of the formulation 
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were captured at a working distance of 9 mm and an accelerating voltage of 25 kV with a JSM-
6510LV-LGS Scanning Electron Microscope (SEM). For the particles made using the 
nanoprecipitation method, the initial sample preparation was slightly modified instead of the 
usual procedure of mounting the particles onto a carbon adhesive tape. Briefly, the nanoparticles 
were dispersed in deionized water and a few suspension droplets were added onto a transparent 
cover slip. This suspension on the cover slip was allowed to evaporate overnight and then the dry 
film of particles were sputter coated and imaged. 
3.3.5 Zeta Potential measurement 
 The nanoparticles made by the PIN method had poor redispersibility in water, whereas 
they were well dispersed when 1% Pluronic F-127 solution was used as the dispersion media. 
Therefore, suspensions of PLGA nanoparticles (0.1% w/v) were prepared in 1% Pluronic F-127 
by bath sonication for 60 seconds. Nanoparticle suspensions were subjected to zeta potential 
analysis on a 90Plus Zeta Potential Analyzer (Brookhaven Instrument Corporation), which uses 
the electrophoretic light scattering and the laser doppler velocimetry method to determine the 
zeta potential.  Average zeta potentials following 10 runs for each formulation were recorded. 
3.3.6 Thermal analysis by DSC 
 The DSC measurements were carried out on a Q2000 series DSC (TA Instruments). A 
heat-cool-heat scan was performed over the temperature range of -40˚C to 220˚C at a rate of 
10˚C/min for each cycle. Data analysis was performed using the Universal Analysis 2000 
software (TA Instruments).  Reported glass transition temperatures (Tg) are from the first heat. 
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3.4 Results 
3.4.1 Phase inversion nanoencapsulation 
The surfactants Span 85 (HLB 1.8), Merpol A (HLB 6), PSH (HLB 10), and Tween 80 
(HLB 15) were used at concentrations of 0.25%, 0.5%, 1%, and 2% v/v as shown in table 5. 
3.4.1.1 Effect of surfactant HLB and concentration on nanoparticle size 
 At a concentration of 0.25% v/v, an increase in HLB value results in an increase in the 
nanoparticle size from 783.6 nm to 1314.5nm. At 0.5% v/v concentration, the nanoparticle size is 
almost same except for HLB value of 15 where the size increases to 1713.7 nm. However, at 1% 
v/v concentration, the nanoparticle size increases from 751.8 nm at HLB 1.8 to 1604.8 nm at 
HLB 6, after which it decreases to 1172.3 nm at HLB 10 (figure 18). 
 With Span 85, there is an increase in nanoparticle size from a concentration of 0.25% to 
0.5% after which the size decreases. For Merpol A, there is an increase in the size with increase 
in the surfactant concentration from 0.25% up to 1% after which the size remains constant. For 
PSH, surfactant concentration doesn’t seem to affect the nanoparticle size significantly. However 
for Tween 80, nanoparticle size increases with concentration wherein at 0.25% concentration the 
nanoparticle size is 1314.5 nm which increases to 1713.7 nm at concentration of 0.5%. At 
concentrations above 0.5%, the nanoparticles were not able to be dispersed for sizing. Therefore, 
it was not possible to analyze the nanoparticle size at these higher concentrations. This difficulty 
in redispersibility of nanoparticles at higher concentration may be as a result of extensive 
aggregation at these higher concentrations (figure 18). 
3.4.1.2 Effect of HLB and surfactant concentration on Tg of nanoparticles 
 The Tg for control nanoparticles without surfactant was 36.7˚C. In formulations with 
surfactant of HLB 1.8, the Tg was higher than that for control ranging from 39.8 to 43.13. At this 
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HLB, the surfactant concentration has no noticeable trend on the Tg. In formulations with 
surfactant of HLB 6, the Tg was higher than that for control only at the lowest concentration of 
0.25% v/v. At all higher concentrations it was lesser than that for control ranging from 31.5 to 
34˚C. At this HLB, an increase in the surfactant concentration resulted in a decrease in Tg. In 
formulations with surfactant of HLB 10, the Tg is higher than that for control ranging from 39.6 
to 40.9˚ C. At this HLB, the surfactant concentration didn’t seem to have a significant effect on 
the Tg. The surfactant with HLB 15 caused a reduction in the Tg as compared to that of control. 
This decrease in Tg followed a concentration dependent manner where an increase in 
concentration resulted in decrease in Tg from 35.8˚C at 0.25% concentration to 28.7˚C at a 
concentration of 2% (figure 19). 
3.4.1.3 Effect on surfactant on zeta potential 
 The surfactant doesn’t seem to have a significant effect on the zeta potential of the 
nanoparticles except that formulations with surfactant had a higher zeta potential than that of 
control (-14.2 mV). As shown in figure 20, the zeta potential for nanoparticle with PSH ranges 
from -17.4 to -20.5 mV. There is not a significant change in the zeta potential with different 
concentration of surfactant used. This observation is likely to be same for formulations with all 
other surfactants used in the study. 
3.4.1.4 Scanning electron microscopy imaging of nanoparticles 
 All formulations were imaged with SEM.  Some representative images are shown in 
figure 21. The smallest formulation was obtained by incorporation of Span 85 at a concentration 
as low as 0.25% v/v.  These nanoparticles are shown to be discrete spherical particles and likely 
have a bimodal distribution with many small particles and a few larger particles with a measured 
average size of 783.6nm (figure 21B). Representative SEM images of nanoparticle formulations 
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made with the other three surfactants are shown in figure 21C-F. Formulations with low Tg 
(S13-S16, S5-S7) were seen to be heavily aggregated and fused (figure 21E and 21F). 
Regardless of the surfactant used, incorporation of surfactant resulted in aggregated and fused 
particles to a varying degree based on the type and concentration of surfactant used. This was 
evident even in particles with relatively higher Tg as is shown for formulation S4, Tg of 42.7oC, 
in figure 21B. The control formulation with no surfactant also had extensively fused 
nanoparticles (Figure 21A). 
3.4.2 Emulsion method and nanoprecipitation method 
The emulsion method yielded nanoparticles of mean size 501±31 nm with a narrow size 
distribution and low polydispersity index. Figure 22A shows an SEM image of these 
nanoparticles wherein the particles are spherical in shape with a smooth surface. There is very 
little to no fusion between the particles. These nanoparticles showed excellent redispersibility in 
water upon sonication.  
The nanoprecipitation method yielded particles of mean size 215±18 nm with a narrow size 
distribution and excellent polydispersity index (~0.1). The SEM image of these particles is 
shown in figure 22B. As seen in the image, the particles appear spherical in shape and are 
discrete. Due to the method by which the sample was prepared, the PVA likely forms a 
continuous layer around the particles. This is likely an artifact of the sample preparation and does 
not represent any structural fusion of the particles in actuality.  
3.5 Discussion 
 The PIN method is a rapid, simple technique of formulating polymer nanoparticles 
without the use of an aqueous phase lending great potential to encapsulation of hydrophilic 
molecules including proteins and peptides. Unlike conventional methods of encapsulation, this 
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method eliminates the shear stress on the agents to be encapsulated, thereby improving the 
physical stability and integrity of sensitive macromolecules like proteins and peptides. Using this 
method, nanoparticles of sizes ranging from 683.2nm-1713.7nm were produced. From figure 21, 
we observe that surfactant HLB and concentration play an important role in controlling 
nanoparticle size.  Therefore, the use of a non-ionic surfactant during PIN fabrication of PLGA 
nanospheres resulted in formulations with varied properties such as size, thermal properties, and 
morphology. 
 When compared to control, in general the addition of surfactants resulted in an increase 
in the nanoparticle size except for span 85 at 0.25, 1, and 2% v/v concentrations where the 
nanoparticle size is almost the same as that for control formulation. From figure 21, it is clear 
that for HLB value greater than 6, there is a marked increase in the degree of fusion of the 
formed nanoparticles. Therefore incorporation of non-ionic surfactants of HLB value less than 6 
provides an option to manipulate the nanoparticle size and reduce fusion/aggregation of 
nanoparticles.   
 There was a general trend of particle size increase with increasing surfactant 
concentration.  The role of surfactants in nanoparticle formulation is commonly to reduce surface 
tension of immiscible liquids, typically reducing the particle size that can be achieved [16]. In 
the PIN method, where both phase are miscible, we believe that surfactants play a similar role by 
reducing the initial droplet size formed resulting in the observation of reduced particle size.  
However, we hypothesize that surfactants also increase the curing or hardening time of the 
nanoparticles allowing greater opportunity of droplet interaction and coalescence prior to 
hardening.  This may account for the observed increase in particle size with increased surfactant 
concentration and is further supported by the observation of fusing in some nanoparticle 
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formulations as imaged by SEM (figure 21F).  This hypothesis is further backed by the Tg 
results as will be discussed further. Figure 21 B and C show SEM images of nanoparticles 
prepared by incorporating the surfactants of HLB value 1.8 and 6. From these SEM images of 
these two formulations it appears as though the most of the nanoparticles are in the size range of 
less than 500 nm. However, due to the particles being fused at some degree, the hydrodynamic 
size as shown by DLS is greater than the actual particle size as could be evidenced by the SEM 
image. This suggests that the hydrodynamic diameter data for the particles might be an 
overestimate of the actual size of individual particles due to the fusion between particles. With 
regards to this observation, it would be interesting to see whether important properties of these 
particles such as drug release and degradation would follow a pattern mimicking that of their 
actual size or that of the fused structure. 
As HLB value of a surfactant increases, its hydrophilic character increases. PLGA is a 
hydrophobic polymer and surfactants of higher HLB as a result of their hydrophilic character 
have a relatively lesser association with the particle surface when compared to surfactants with 
lower HLB. Therefore, in the case of formulations with higher HLB values (10 and 15) this 
might be another reason for extensive fusion of the nanoparticles as the surfactants fail to 
perform the function of stabilization of the nanoparticle. Studies evaluating the degree of 
adsorption of surfactants onto the particle surface will be able to test this hypothesis.  
 A critical parameter in polymeric nanoparticle formulations is the Tg as it will impact 
polymer degradation [17], thereby affecting the drug release. For many medical applications a Tg 
higher than body temperature, 37oC, would be desired.  Interestingly, for HLB values of 15 and 
6, the Tg is lower than 37oC. Whereas for HLB value of 1.8 and 10 the Tg is greater than 37oC. 
Therefore, the ability to modulate Tg would be critical for many medical applications. Surfactant 
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incorporation into polymers has long been used as a “plasticizer” to effectively reduce Tg and 
make rigid polymers more flexible and rubbery [18]. For half the formulations described here, 
the incorporation of surfactant actually substantially increased the measured Tg of the 
formulation ranging from 36.7oC (nanoparticles with no surfactant) to above 40oC as seen in 
figure 19.  This may indicate that the surfactants are truly interacting at the interfacial surface 
and are not being fully incorporated into the polymer nanoparticles. These results support our 
hypothesis that some surfactants increase the cure time.  This increase in cure time, or slowing of 
hardening, would allow polymer organization within each droplet effectively increasing the Tg.  
This effect is likely mitigated at high concentrations of surfactant due to an increase of surfactant 
incorporation into the nanoparticles, where they act as plasticizing agents.  The ability to 
modulate Tg of polymer nanoparticles may prove useful in the control of degradation and cargo 
release for medical applications. 
 When considering the zeta potential for all the formulations there were no evident trends 
beyond the observation that for representative formulations with a surfactant (S25-S36) the zeta 
potential was higher compared to the PLGA nanoparticles without surfactant (-14.3mV) and 
ranged from -17.4mV to -20.5mV as seen in figure 20. 
 Using the PIN method, nanoparticles of PLGA polymer were obtained though there was 
some degree of fusion among the particles. This method is particularly advantageous for the 
encapsulation of sensitive therapeutics such as nucleotides and proteins. The reason being that 
the other existing methods of nanoparticle fabrication involve a certain degree of stress that is 
detrimental to these sensitive therapeutic agents rendering them inactive or greatly reducing their 
activity as a result of damage to the therapeutic agent. For this reason, the PIN method offers a 
convenient solution for the encapsulation of such sensitive therapeutics since it doesn’t involve 
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any external agitational forces on the active agents and the solvent exposure is very minimal as 
compared to that encountered in other commonly used methods. Though in the scope of this 
study, we have seen fusion of particles with each other, discrete particles can be obtained by fine 
tuning the fabrication method further by using the variables we have used in this study and also 
by looking at other variables that play a role in the nanoparticle formation. Using the polymer 
poly (fumaric-co-sebacic anhydride), Furtado et. al. have obtained discrete polymer 
nanoparticles of a small size and very little to no fusion between particles [19]. Therefore, the 
PIN method has great potential for the formulation of nanoparticles encapsulating sensitive 
therapeutic agents.  
 Nonetheless, within the boundaries of the parameters we tested, the particles obtained in 
our study were fused to a certain extent. Therefore, we decided not to utilize those particles for in 
vivo studies due to the fact that they have the potential to cause severe aggregation and blockage 
of blood vessels upon intravenous administration which could be lethal to the animal. 
Accordingly, we proceeded with other methods for nanoparticle fabrication for our in vivo 
nanoparticle biodegradation studies which are discussed in chapter 4. The particles used for the 
in vivo degradation studies were produced by an emulsion method and nanoprecipitation method. 
When compared to particles made by PIN method, the nanoparticles fabricated by the two 
mentioned methods had a smooth surface with little to no fusion between particles. These 
particles also had a negative surface charge similar to that of the polystyrene nanoparticles that 
were used in the lung biodistribution studies that are discussed in chapter 2. Furthermore, the 
particles prepared by PIN method had extremely poor redispersibility in aqueous media unless a 
solution of 1% pluronic F-127 was used for dispersion of these nanoparticles. On the other hand, 
the nanoparticles made by the emulsion method and nanoprecipitation method were easily 
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redispersed in normal saline upon sonication. As a result of the excellent properties of the 
nanoparticles prepared by these two methods (emulsion method and nanoprecipitation), these 
formulations were used for the in vivo biodegradation studies discussed in the following chapter. 
 
 
 
Figure 18.  Size of all nanoparticle formulations (n=3, mean±SEM).  
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Figure 19.  Glass transition temperatures (Tg) for all formulations.  The line indicates the 
Tg for nanoparticles fabricated without surfactant (36.7oC). (n=3, mean±SEM) 
 
 
Figure 20.  Zeta potentials of nanoparticle formulations with incorporation of PSH. (n=3, 
mean±SEM) 
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Figure 21. SEM images of the PLGA nanoparticles of formulations (A) C at 
magnification of 20,000X (B) S11 at a magnification of 15,000X, (C) S22 at a magnification 
20,000X; (D) S36 at a magnification 20,000X, (E) S48 at 10,000X, (F) S13 at a magnification of 
10,000X. 
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Figure 22. SEM images of PLGA nanoparticles of size (A) 500 nm made by emulsion 
method and (B) 200 nm made by nanoprecipitation method respectively at magnification of 
30,000X. 
 
Surfactant HLB Formulation 
ID 
Surfactant 
Conc. (%v/v) 
Span 85 1.8 
S1 
S2 
S3 
S4 
2.00% 
1.00% 
0.50% 
0.25% 
Merpol A 6 
S5 
S6 
S7 
S8 
2.00% 
1.00% 
0.50% 
0.25% 
Polyoxyethylene 
sorbitol 
hexaoleate 
10 
S9 
S10 
S11 
S12 
2.00% 
1.00% 
0.50% 
0.25% 
Tween 80 15 
S13 
S14 
S15 
S16 
2.00% 
1.00% 
0.50% 
0.25% 
No surfactant C None 
 
Table 5. Formulation parameters of PLGA nanoparticles prepared by PIN method.  
3.6 Conclusions 
The PIN method is a very useful method, particularly when considering the encapsulation 
of hydrophilic drugs, including proteins and peptides, due to the absence of an aqueous phase 
and reduced shear stress.  It has been demonstrated to effectively encapsulate hydrophobic drugs, 
insulin and genetic material [10]. We show here that the incorporation of surfactants in the PIN 
method can modulate nanoparticle size, thermal properties and zeta potential.  These parameters 
were affected by the surfactant HLB and surfactant concentration.  Since surfactants likely play a 
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key role in drug loading, drug stabilization and drug release, further studies should be done with 
this system including the incorporation of various cargos.  The PIN method is a versatile 
nanoparticle fabrication method that can produce polymer nanoparticles of greatly varied 
properties to suit the desired application. The utilization of surfactants enhances this ability 
further. 
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 CHAPTER 4 
4.1 Introduction: 
Nanoparticle systems have tremendous potential in clinical applications and there are 
already several successful nanoparticle systems in use for various diseases [1]. The in vitro 
degradation of PLGA microparticles and nanoparticles has received significant attention from a 
quantitative as well as qualitative standpoint [2-4]. However, to the best of our knowledge, there 
are no previous reports quantitatively examining the in vivo degradation of biodegradable 
microparticles or nanoparticles in tissues post systemic administration i.e. distributed 
nanoparticles or microparticles. The lack of quantitative information on in vivo degradation, an 
important parameter controlling the drug release, makes it difficult to design optimal drug 
delivery systems with predictable drug release properties in target tissues.  
Conventionally, the drug release from PLGA nanoparticles in vitro is used as a basis to 
predict a release in vivo. However, it must be noted that in vitro drug release need not be the 
same as that in vivo. For instance, the role of enzymes in PLGA degradation is still debated [5-7]. 
Given the fact that nanoparticle degradation plays a crucial role in sustained drug release [8], we 
wanted to determine the in vivo degradation of PLGA nanoparticles post intravenous 
administration. This specific aim would provide us with a platform for developing efficient 
polymeric nanoparticle based drug delivery systems.  
Accordingly, we have investigated the in vivo biodegradation of PLGA nanoparticles of 
mean sizes 215±18nm and 501±31nm post intravenous administration; for ease of understanding, 
these sizes will hereafter be referred to as 200nm and 500nm respectively. After intravenous 
administration of nanoparticles, the tissues were extracted at time points of 3, 24, 72 hours, and 1 
week. The decrease in weight average molecular weight (Mw) is a manifestation of ester bond 
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scission in the polymer backbone which has a positive effect on the drug release from a 
nanoparticle system encapsulating a drug. This degradation information can also be obtained for 
other types of PLGA such as that shown in a recent study where PLGA copolymer type (random, 
sequenced) had a significant effect on its in vitro degradation [9]. Apart from PLGA, this method 
can also be applied to other degradable polymer systems including polyanhydrides, polyamides, 
polyesters, poly(cyano acrylates), polyurethanes, poly orthoesters, polydihydropyrans, 
polyacetals etc.  
4.2 Materials 
PLGA of molecular weight (Mw) 44,000 Da was provided by Purac Biomaterials (USA). 
Polyvinyl alcohol (PVA) of molecular weight 88,000 Da and phosphate buffered saline 
(PBS; pH 7.4) was purchased from Fisher Scientific (USA). All other organic solvents 
were obtained from Fisher Scientific and were of HPLC grade. 
4.3 Methods 
4.3.1 Fabrication and characterization of PLGA nanoparticles 
The methods of preparation of the PLGA nanoparticles used in this study and their 
characterizations are detailed in section 3.3.2, 3.3.3, and 3.3.4 of chapter 3.  
4.3.2 In vitro degradation of PLGA nanoparticles 
For in vitro degradation, 10 mg of the PLGA nanoparticles was suspended in 1.25 ml of 
PBS and incubated at 37˚C on a mixer. The samples were removed from the incubator at pre -
determined time points and lyophilized. Dried samples were dissolved in chloroform and 
subjected to analysis by gel permeation chromatography (GPC) (GPC Max VE 2001, Viscotek 
Corporation) equipped with a column bank consisting of three columns with size exclusion limits 
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of 4 million, 70,000, and 5,000 Da. A refractive index (RI) detector (VE 3580, Viscotek 
Corporation) was used for PLGA detection. 
4.3.3 Preparation of nanoparticle suspension and intravenous administration 
The nanoparticles were suspended in sterilized 0.9% sodium chloride solution at a 
concentration of 3% w/v and sonicated in a water bath for 30 minutes. Once the nanoparticles 
were well suspended, they were stored at 4˚C until further use (a maximum of 5 minutes). Before 
administration of nanoparticles to each animal, the formulation was sonicated for about 10 
minutes. Degradation analysis yielded no degradation of nanoparticle formulations following this 
suspension method. Male Balb/c mice weighing between 20-25 g (Charles River Inc.) were used 
following acclimation for a week. Food and water were available to the animals ad libitum.  
 
The PLGA nanoparticles in suspension were administered to the mice via tail vein 
injection. Each animal received 300µl of the nanoparticle suspension. For all the study groups n 
= 3. All animal experiments were conducted in accordance to the Institutional Animal Care and 
Use Committee at Wayne State University.  
4.3.4 Harvesting tissues and sample preparation 
Tissues including liver, spleen, kidneys, heart, brain, lungs, and lymph nodes (axillary, 
brachial, cervical, and mesenteric lymph nodes) were extracted, processed, and analyzed by a 
method similar to that described earlier [10]. Briefly, the harvested tissues were homogenized 
and lyophilized. Chloroform was added to the lyophilized tissue and placed on a mixer for 96 
hours at room temperature. This was done to ensure the complete dissolution of PLGA in 
chloroform. After the extraction step, the mixture was filtered using a 0.2 µm filter and 
chloroform was frozen and lyophilized. This polymer extract was then subjected to analysis by 
GPC after dissolving it in THF.  
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4.3.5 Assay for biodegradation and biodistribution of nanoparticles in vivo 
Analysis of polymer concentration and molecular weight determination from tissue 
extracts was performed by GPC as described above for in vitro degradation (section 4.3.2).  A 
refractive index (RI) detector (VE 3580, Viscotek Corporation) was used for PLGA detection. 
For calculation of the molecular weight of PLGA in tissues, the peak retention time was 
calculated by the Omni SEC software, and the molecular weight of the polymer in vivo was 
determined by means of a calibration curve of retention time versus log molecular weight of 
narrow standard polystyrene samples of molecular weights ranging from 1000 to 90000 Da. For 
biodistribution of nanoparticles in vivo, the area under the curve was calculated by Omni SEC 
software and the amount of nanoparticles present in each tissue was calculated as a percent of the 
administered dose. In order to ensure that the degradation observed is not as a result of tissue 
processing, a sample of PLGA nanoparticles were processed directly and no degradation was 
observed upon GPC analysis of the same. 
4.3.6 Statistical analysis 
Statistical analysis was performed using one-way ANOVA followed by Tukey’s post-hoc 
analysis where applicable, with OriginPro8 software. 
 
4.4 Results and discussion 
 
4.4.1 In vivo biodegradation of PLGA nanoparticles post intravenous administration 
For both the tested nanoparticle sizes, the liver was the site of highest nanoparticle 
deposition followed by spleen and lungs. Therefore, we further determined the degradation of 
nanoparticles in these most relevant tissues. Among all the tissues studied, degradation in the 
liver is highest (figure 23 and 24). For the 500 nm nanoparticles, the weight-average molecular 
weight (Mw) by 3 hours and 24 hours was 36,879 Da and 40,427 Da respectively. However, it 
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decreased to 31,377 Da by 72 hours and further decreased to 23,623 Da at the end of 1 week. 
The next highest degradation of nanoparticles was seen in spleen wherein, at the end of 3 hours 
and 24 hours, the Mw was 39,557 Da and 38,111 Da respectively. However, it decreased to 
35,076 Da by 72 hours and further decreased to 28,153 Da at the end of 1 week. For these three 
tissues it is interesting to note that the degradation seems to have a lag phase up to at least 24 
hours after which we see a decrease in the Mw by 72 hours. For the 200nm size nanoparticles, 
extensive degradation was observed in the liver. The Mw at the end of 3 hours and 24 hours was 
37,970 Da and 37,417 Da respectively. Thereafter, it decreased to 31,192 Da by 72 hours and 
24,116 Da at the end of 1 week. In spleen, the Mw at the end of 3 hours and 24 hours was 38,449 
Da and 39,704 Da respectively; however by 72 hours the Mw decreased to 31,633 Da; it then 
increased to 34,557 Da at the end of 1 week (figure 24).  
From the in vitro degradation data, the 500 nm nanoparticles have a faster rate of 
degradation as compared to 200 nm nanoparticles (figure 25). A similar size-based degradation 
difference has been reported by Dunne and co-workers. This is because in larger sized 
nanoparticles, the degraded polymer fractions have a longer path to diffuse to the nanoparticle 
surface resulting in accumulation of these oligomers leading to autocatalysis of PLGA chains. In 
the case of smaller particles the degraded fractions diffuse out much faster [8]. This is thought to 
be the reason for larger sized particles having a faster degradation. However in vivo, in the liver 
there is little difference in the degradation pattern of the two nanoparticle sizes with the 500 nm 
nanoparticles having a slightly higher degradation at the end of one week where the Mw for 500 
nm is 23,623 Da whereas that for the 200 nm nanoparticles is 24,116 Da. In the spleen, for the 
first two time points of 3 hour and 24 hours there is little difference in the Mw between both the 
sizes. At 3 hours, the Mw for 500 nm and 200 nm nanoparticles was 39,557 Da and 38,449 Da 
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respectively. At the end of 24 hours the Mw was 38,111 Da and 39,704 Da for 500 nm and 200 
nm size nanoparticles in spleen, respectively. Furthermore at the 3 day time point, the 200 nm 
nanoparticles shows a higher degradation where the Mw is 31,633 Da as compared to 35,076 Da 
for the 500 nm size. However, at the end of 1 week the 500 nm nanoparticles are degraded to a 
larger extent as compared to the 200 nm nanoparticles with the Mw being 28,153 Da and 34,557 
Da respectively. Furthermore, it should be noted that the 500 nm nanoparticles have a higher 
deposition in the liver, and that the 500 nm nanoparticles in general have shown a slightly higher 
in vivo degradation than the 200 nm nanoparticles. In the liver, the 500 nm nanoparticles have a 
35.9% reduction in the Mw at the end of 1 week and the 200 nm nanoparticles had a 36.4% 
reduction in Mw as compared to that at the initial time point of 3 hours. However, in the spleen, 
500 nm nanoparticles had a higher degradation as compared to that for 200 nm size. Relative to 
the Mw at 3 hours, the 500 nm nanoparticles have a 28.8% reduction in Mw at the end of 1 week 
whereas the 200 nm nanoparticles only have a decrease of 10.1% at the end of 1 week. Taken 
together, this suggests that the 500 nm nanoparticles have a much faster in vivo degradation rate 
than that of 200 nm nanoparticles in the spleen. On the other hand, in the liver, the nanoparticle 
size did not seem to affect its biodegradation pattern. The higher amount of nanoparticle 
degradation observed in the liver over other tissues may be attributed to the presence of higher 
concentrations of several esterases in the liver [11]. Therefore, as a result of differences in the 
enzymatic diversity and concentration in these different tissues, the degree of degradation is 
expected to vary based on the amount of enzymes in these tissues with liver being the tissue with 
the highest nanoparticle biodegradation. In addition to the differences in enzymatic make up, the 
liver has the highest nanoparticle deposition followed by spleen and lungs. Therefore, based on 
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these considerations and the biodegradation observed in tissues, the order of nanoparticle 
degradation in the three tissues can be generalized as: liver>spleen.  
PLGA degrades by hydrolysis of its ester bonds and the polymer degradation results in 
the decrease of Mw and Mn. As the long polymer chains are broken down, the Mw and Mn 
decrease except in cases where a considerable proportion of the oligomeric fractions are lost; in 
such a situation the Mw and Mn increase. If the Mw shows a decrease with time and Mn stays 
fairly constant, it could be an indication that the oligomeric fractions are resistant to hydrolytic 
degradation. This observation was made by santos et. al. [12] in the degradation of poly 
(fumaric-co-sebacic anhydride) microspheres where the Mn stayed fairly constant over the course 
of the study while the Mw decreased substantially over time. They have attributed this 
observation to be a result of the oligomers being more stable to hydrolytic attack as compared to 
longer polymer chains. A similar observation is encountered in our in vivo degradation studies. 
For the 200 nm PLGA nanoparticles in the liver, the Mn is relatively constant up until 24 hours 
after which it decreases till 7 days. This indicates that in the liver, the oligomeric fractions 
undergo a pronounced degradation after 24 hours. In spleen the Mn values suggest that the 
oligomeric fractions degrade after 24 hours up until 3 days and then the Mn remains fairly 
constant. However, the Mw shows a substantial increase from 3 days to 7 days. This Mw and Mn 
taken together suggest a possibility of the oligomeric fractions leaving the tissue after 3 days due 
to which there is an increase in Mw however the Mn remains relatively constant due to new 
oligomers being created from the long chain polymer degradation.  
In the case of 500 nm PLGA nanoparticles in liver, the Mn stays relatively stable until 24 
hours after which it decreases until 7 days. This suggests that the oligomeric fractions degrade 
after 24 hours thereby resulting in a decrease in the Mn, similar to that of 200 nm PLGA 
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nanoparticles in the liver. In spleen the Mn is relatively stable until 3 days after which it 
decreases by the end of 7 days. This suggests that the oligomers are fairly resistant to hydrolytic 
attack at least until 3 days after which they degrade further. 
The polydispersity index (PDI) (among several other parameters) of PLGA in the liver 
and spleen is shown in table 6. For both the nanoparticles (200 nm and 500 nm), the PDI in 
spleen in higher than that in the liver. This indicates that the oligomeric fractions may be retained 
in the spleen to a higher extent whereas in the liver they might be released into circulation and 
new oligomeric fractions are created which keeps the PDI relatively constant. The amount of 
PLGA nanoparticles deposited in the liver is significantly higher than that in the spleen. 
Therefore, though the oligomers leave the liver, there are more oligomers created which would 
prevent the PDI from increasing. The Mw, Mn, and PDI information for the in vivo tissue 
degradation of PLGA nanoparticles not only elucidates the polymer degradation over time but 
also provides insights into the finer details of the pattern of degradation happening with time. 
On the whole, this type of information on the in vivo tissue biodegradation provides 
critical insights with respect to the extent of polymer degradation in tissues which in turn has an 
impact on the drug release in the tissues. In addition, such information also gives insights about 
the toxicity potential of the drug delivery system in tissues. Determination of nanoparticle 
degradation in tissues could greatly improve the design of drug delivery systems and also lend 
important insights about nanoparticle toxicity potential in general.  
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4.4.2 Degradation kinetics of PLGA nanoparticles 
It has been demonstrated in several studies that the hydrolytic degradation of poly lactic 
acid, poly glycolic acid, and their copolymer PLGA follows first order kinetics [13, 14]. The first 
order degradation pattern can be represented by the following equation:  
M = Mo (e-kt)     Eq. (1) 
In the above equation, M is the molecular weight of the degrading polymer at time t, k is 
the rate constant of degradation, Mo is the initial molecular weight of the polymer. Plotting Ln 
(Mw) against time for the in vitro degradation study gives the profiles depicted in figure 26. The 
data when fitted for linearity gives r2 values of 0.9969 and 0.9606 for 500 nm and 200 nm size 
respectively (table 7). This indicates that the in vitro degradation of PLGA nanoparticles of both 
the sizes follows first-order linear kinetics. The in vitro rate of degradation of 500 nm size 
nanoparticles is 2 times faster than that of 200 nm nanoparticles (figure 26). 
In the in vivo study, when the Ln (Mw) was plotted against time and the data fitted for 
linearity, r2 values were obtained that suggest the in vivo degradation in the liver and spleen 
followed first order degradation pattern. For 500 nm size nanoparticles in liver and spleen the r2 
values were 0.9233 and 0.9954 respectively. Similarly, for the 200 nm size nanoparticles in liver 
and spleen the r2 values were 0.9899 and 0.9669 respectively (table 7). Important comparisons 
arise when the degradation rates in tissues in vivo and those in vitro are compared for each 
nanoparticle size. The 500 nm nanoparticles in liver have a rate of degradation similar to that of 
in vitro, whereas in spleen the rate of degradation is 0.67 times that in vitro. On the other hand, 
the 200 nm nanoparticles in liver have a degradation rate that is 1.88 times that in vitro and the 
nanoparticles in spleen have a degradation rate that is 2 times higher than that in vitro (table 8). 
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Taken together, these observations suggest that smaller size PLGA nanoparticles degrade almost 
twice as fast in the liver and spleen as compared to their in vitro degradation in PBS whereas the 
500 nm nanoparticles in liver have similar degradation pattern as that in vitro. However in spleen 
they degrade at a rate slower than that in vitro. Furthermore, when comparisons are made 
between the rate constants between tissues for each size, we see that the rate of degradation for 
500 nm nanoparticles is 1.5 times higher than that for 200 nm nanoparticles in the liver. Whereas 
in the spleen, both the nanoparticle sizes have almost similar rate of degradation where the 
degradation rate for 500 nm nanoparticles is 0.93 times that for 200 nm nanoparticles (table 8). 
Thus, the molecular weight data and information of degradation kinetics together give important 
insights into the pattern of nanoparticle degradation in tissues and help establish correlation of in 
vivo degradation with the in vitro degradation. Additionally, it allows for the establishment of 
correlation of degradation between several nanoparticle systems with varying physiochemical 
properties. Therefore, such mathematical treatment of real time degradation information helps 
predict the in vivo degradation pattern of particular nanoparticle systems in tissues at specific 
time points. Additionally it also gives an estimate of the amount of drug released by a particular 
time period since degradation is an important parameter affecting the drug release.  
4.4.3 Biodistribution of PLGA nanoparticles following intravenous administration 
For both the nanoparticle sizes, liver was the site of highest deposition followed by 
spleen and lungs (figures 27 and 28). This result is in good agreement with the established fact 
that nanoparticles with hydrophobic surfaces are rapidly sequestered by the organs of 
reticuloendothelial system (RES) from the circulation [15]. The larger size nanoparticles deposit 
in the liver in larger amounts as compared to the 200 nm nanoparticles. This is also in agreement 
with the fact that the optimum size for phagocytic (macrophage) uptake is 250 nm to 3 microns 
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[16]. The 500 nm PLGA nanoparticles have a higher deposition in liver at 45.9% of the 
administered dose (figure 27) which could be a result of more efficient uptake by Kupffer cells 
of liver, while the 200nm nanoparticles have a liver deposition of 32.3% at the end of 3 hours 
(figure 28). In accordance with this observation, there have been reports showing larger sized 
nanoparticles having a higher accumulation in the liver [17, 18]. However, in the spleen, 
nanoparticles of both sizes have a similar amount of deposition at 10.1% and 10.5% of 
administered dose at the end of 3 hours (figures 27 and 28). The amount of nanoparticles in 
these tissues decreases with time and is likely a result of degradation and subsequent removal of 
the monomers from these organs in addition to possible redistribution of nanoparticles to other 
tissues. The decrease in the amount of nanoparticles over time and the overall mass loss in all the 
tissues combined are shown (figures 29 and 30). Knowledge of biodegradation coupled with that 
of biodistribution is a powerful tool in designing efficacious drug delivery systems as it throws 
light on the pharmacokinetics of the nanoparticle systems. As discussed earlier, different organs 
have different nanoparticle disposition and degradation rates. Therefore, information regarding 
tissue disposition of the nanoparticles alone does not comprise the full situation of nanoparticle 
pharmacokinetics. Since the nanoparticles degrade in tissues and are eliminated/excreted, 
knowing the biodegradation coupled with the biodistribution will give a true understanding of 
the pharmacokinetics of degradable nanoparticle systems and also the tissue pharmacokinetics of 
drugs carried by the nanoparticles. All of this information will have a direct positive impact on 
the design of polymeric drug delivery systems including safety considerations. 
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Figure 23. The biodegradation of PLGA nanoparticles of size 500 nm in diameter. (n=3; 
mean ± s.d). ‘*’ – statistically significant (p<0.05). In order to ensure that the degradation 
observed is not as a result of tissue processing, the PLGA nanoparticles were processed and 
observed no degradation upon GPC analysis of the same. 
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Figure 24. The biodegradation of PLGA nanoparticles of size 200nm in diameter. ‘*’ – 
statistically significant, p<0.05 (n=3;mean ± s.d). In order to ensure that the degradation 
observed is not as a result of tissue processing, the PLGA nanoparticles were processed and 
observed no degradation upon GPC analysis of the same. 
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Figure 25. In vitro degradation profile of PLGA nanoparticles (n=3;mean ± s.d).  
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Figure 26. This figure represents a plot of Ln(Mw) versus time for the in vitro 
degradation of nanoparticles of the two sizes. The data was subjected to linear fit and r2 values 
confirm the linearity of the data. 
 
96 
 
 
Figure 27. Biodistribution of PLGA nanoparticles of mean size 500nm after intravenous 
administration. ‘*’ means statistically significant, p< 0.05 (n=3; mean ± s.d). SI-Small intestines, 
Sal. – Salivary. 
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Figure 28. Biodistribution of PLGA nanoparticles of mean size 200 nm after intravenous 
administration. ‘*’ means statistically significant, p< 0.05 (n=3; mean ± s.d).  
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Figure 29. Total amount of nanoparticles detected from all tissues represented as the 
percentage of the administered dose recovered. ‘*’ means statistically significant, p< 0.05 (n=3; 
mean ± s.d). 
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Figure 30. Percent decrease in the total amount of nanoparticles detected from all the 
tissues at the three time points (1, 3, 7 days) relative to the amount deposited at 3 hours. ‘*’ 
means statistically significant, p< 0.05 (n=3; mean ± s.d). 
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Size 
(nm) Tissues Time (h) Mw (Da) Mn (Da) Mp (Da) Mz (Da) PDI 
200 
Liver 
3 37970±3870 29472±2686 28086±1881 52871±8184 1.29±0.02 
24 37417±4285 29960±4651 24960±5802 48914±3910 1.25±0.05 
72 31192±1925 25321±884 24784±624 40485±5110 1.23±0.04 
168 24116±155 20922±210 15415±2460 28633±590 1.15±0.01 
Spleen 
3 35547±4330 22855±6789 35697±1138 52938±1624 1.48±0.22 
24 30891±1601 14228±2180 33361±1087 59964±6107 1.41±0.13 
72 25934±1371 15074±1315 27915±1575 42224±905 1.35±0.06 
168 30318±4058 21386±1183 16439±4957 49348±12776 1.51±0.15 
500 
Liver 
3 36879±4801 29708±3881 27210±1064 48222±7853 1.24±0.02 
24 40427±3742 31728±2200 29139±4253 55697±7987 1.27±0.03 
72 31377±2059 26535±2220 22245±3179 38509±2469 1.18±0.03 
168 23623±169 20272±373 18547±434 28170±345 1.16±0.01 
Spleen 
3 39557±3811 27190±4057 34530±2423 58663±8400 1.46±0.11 
24 38111±4371 25213±4552 34166±2283 65864±13231 1.53±0.16 
72 35076±3718 25068±906 27315±2965 52779±10770 1.40±0.10 
168 28153±1816 21155±265 21799±2271 41299±6650 1.33±0.09 
 
Table 6. Molecular weight information of PLGA nanoparticle degradation in the liver 
and spleen at the respective time points after administration intravenously (n=3; mean ± s.d). 
 
Size (nm) r
2 
Liver Spleen In vitro 
500 0.9233 0.9954 0.9969 
200 0.9899 0.9669 0.9606 
 
Table 7. Calculated r2 values from the plot of Ln(Mw) versus time for the degradation in 
liver, spleen, and in vitro degradation. 
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Size (nm) Rate constant (k) (x 10
-3) 
Liver Spleen In vitro 
500 3.1 2.1 3.1 
200 2.9 2.8 1.5 
 
Table 8. First order rate constants of degradation of polymer nanoparticles in tissues and 
in vitro. The rate constants were calculated by plotting Ln(Mw) versus time (t) and the data was 
fitted linearly which then gives slope (k) of the line for each data set. 
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4.5 Conclusions 
In this work, we have successfully shown for the first time the in vivo degradation of 
PLGA nanoparticles in the liver and spleen at several time points after intravenous 
administration. We have been able to show the differences in PLGA nanoparticle degradation by 
tissues and by nanoparticle size. We have been able to obtain the degradation data in tissues for 
parameters such as Mw, Mn, Mz, Mp, and polydispersity index (table 6). For the 500 nm size 
nanoparticles, the in vivo degradation in the liver was shown to occur at a slower rate as 
compared to the in vitro degradation. Whereas in the spleen, the rate of degradation was faster 
than that in vitro. For the 200 nm size nanoparticles, the rate of degradation in both the liver and 
spleen were twice as fast as in vitro. Being able to determine the dynamic degradation of 
nanoparticles in tissues will advance our knowledge of in vivo degradation of nanoparticles with 
regards to properties like size, chemistry, molecular weight etc. Furthermore, from the in vivo 
tissue degradation of nanoparticles and the drug release from nanoparticles in a particular tissue, 
it would be possible to establish a correlation between polymer degradation and drug release. 
This will enable the design of nanoparticle drug delivery systems with precisely predictable 
amounts of drug release in any target tissue. Understanding in vivo biodegradation kinetics of 
polymer nanoparticles will have major implications on drug delivery involving biodegradable 
polymer nanoparticles and microparticles. This method can further be improved and applied not 
only to PLGA based delivery devices, but to any degradable polymers used in biological 
systems. We believe that the combined knowledge of biodistribution and in vivo biodegradation 
of polymeric nanoparticle systems will have a significant impact on the understanding of 
nanoparticle pharmacokinetics and the dynamic property change of nanoparticles in vivo. 
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Further, the application of this work may aid in the rational design of tailored drug delivery 
systems to a target tissue where drug release is degradation dependent. 
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CHAPTER 5 
5.1 Introduction 
 Curcumin, a hydrophobic polyphenol derived from turmeric has been found to have 
several therapeutic applications especially in many types of cancers [1, 2]. It has been shown to 
have an inhibitory effect on the proliferation of several cancer cells [3]. However, due to its 
highly hydrophobic nature which means poor solubility, its bioavailability is poor. Furthermore, 
it is also rapidly metabolized in the body. As a result of these issues, it has found limited success 
in the clinic [4]. Recently, a novel curcumin analogue 3, 4-difluorobenzo curcumin also known 
as Difluorinatedcurcumin (CDF) was sysnthesized by Padhye et. al [5]. The curcumin analogue 
CDF has shown inhibitory activity in cancer cell lines (especially in pancreatic cancer cells) 
apart from inducing apoptosis [5]. Furthermore, it has been shown to possess relatively greater 
bioavailability in systemic circulation and in the pancreas as compared to its precursor curcumin 
[6].   
 Since CDF has been shown to be a chemosensitizer for cancer cells, we had envisioned 
the development of a formulation with co-encapsulation of CDF and doxorubicin (a potent 
anticancer drug with immunomodulatory potential) for treatment of breast cancer. However, due 
to the non-availability of the free base form of doxorubicin, we have encapsulated CDF into 
polymeric nanoparticles made of PLGA with different loading capacities (%w/w) as follows: 
24% (F1), 33% (F2), and 38% (F3). Of these four formulations, the formulation F2 was tested 
for its antiproliferative activity on MDA-MB-231 (breast cancer) and BxPC3 (pancreatic cancer) 
cell lines. In addition to the formulation F2, the antiproliferative activity of free CDF and empty 
PLGA nanoparticles was evaluated. The formulation F2 showed potent antiproliferative activity 
similar to the free CDF. This is notable since at the tested time points, the formulation would 
only be able to release part of the drug encapsulate. This means that the cell growth inhibition 
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observed from the formulation is only resulting from part of the encapsulate drug being released. 
Therefore this observation indicates that the encapsulation of CDF into nanoparticles improves 
the efficiency of CDF in terms of its antiproliferative potential.  
5.2 Materials  
 PLGA (Resomer RG 502H, 50:50) with an inherent viscosity of 0.16-0.24 dL/g was 
obtained from Boehringer Ingelheim (Germany). CDF was gifted by Dr. Fazlul Sarkar, 
Department of Pathology, Barbara Ann Karmanos Cancer Center. Poly (vinyl alcohol) of 
molecular weight 88,000 Da was purchased from Fisher Scientific (USA). All other organic 
solvents were purchased from fisher scientific and were of HPLC grade. 
 Breast cancer cell line MDA-MB-231 and pancreatic cancer cell line BxPC-3 were 
obtained from ATCC (Manassas, VA). Both of these cell lines were maintained in DMEM 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 100 units/ml 
penicillin and 100 µg/ml streptomycin. Cells were cultured in a 5% CO2–humidified atmosphere 
at 37°C.  
5.3 Methods 
5.3.1 Formulation of CDF loaded nanoparticles 
 The CDF loaded nanoparticles were fabricated by the oil-in-water emulsion method. For 
formulation F1, 50 mg of PLGA and 33.3 mg of CDF was dissolved in 2 ml THF. This solution 
was added to 10ml of 2% PVA solution, vortexed and then sonicated for 5 minutes at an output 
of 30 W. This mixture was added to 40 ml of 0.25% PVA solution and left to stir overnight at 
600 rpm. The nanoparticles were centrifuged at 40,000 x g for 90 minutes and were then washed 
with 30ml deionized water thrice following which they were resuspended in 15ml of deionized 
water, frozen and lyophilized. 
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 For formulation F2, 50mg of PLGA and 21.5 mg of CDF was dissolved in a mixture of 
0.5 ml DMSO and 1.75 ml Ethyl acetate. This solution was added drop wise to 4 ml of 4% PVA 
while the PVA solution was being vortexed at the highest speed setting. This mixture was then 
sonicated over an ice bath for 3 minutes at an output of 30W. This mixture was then added to 
100 ml of 0.25% PVA at 800 rpm overnight on a magnetic stir plate. The nanoparticles were 
centrifuged at 40,000 x g for 90 minutes and were then washed with 30ml deionized water thrice 
following which they were resuspended in 15ml of deionized water, frozen and lyophilized. 
 In the case of formulation F3, 50 mg of PLGA and 33.3 mg of CDF was dissolved in a 
mixture of 1 ml of Ethyl acetate and 1 ml of DMSO. This mixture was added drop wise to 4 ml 
of 4% PVA solution while it was being vortexed. The mixture was then sonicated on an ice bath 
for 3 minutes at an output of 30 W. this was added to 100 ml of 0.25% PVA solution at a stirring 
speed of 600 rpm overnight. 
5.3.2 Determination of drug loading 
 In order to determine drug loading in the nanoparticle and microparticle formulations, a 
known amount of the formulation was dissolved in acetone and the absorbance was determined 
at a wavelength of 360 nm. The drug loading was calculated according to the formula: 
Loading = (Amt. of drug in formulation/Total amt. of the formulation)*100 
5.3.3 Determination of particle size 
 The formulations were either sized directly right after preparation or were lyophilized and 
reconstituted with 1% PVA solution to make 1% w/v dispersion and sonicated for 30-60 seconds 
in a bath sonicator to disperse the nanoparticles. The dispersion was then subject to size analysis 
on a 90Plus Particle Size Analyzer (Brookhaven Instrument Corporation). Mean values 
following 5 runs for each formulation were recorded. 
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5.3.4 Determination of drug release 
 A known amount of the formulation was dispersed in PBS containing 2.5% Tween 80 
and incubated at 37˚ C. Tween 80 was used in the release media as CDF had very poor solubility 
in water and determination of release was not feasible if the release was conducted in PBS alone. 
At pre-determined time point of 1, 3, 6, 12, 24, 36 hours, and then 2, 3, 4, 5, 6, and 7 days the 
sample was centrifuged, supernatant was collected and analyzed by UV spectrometry to 
determine the amount of drug released. Fresh media (PBS containing 2.5% Tween 80) was 
replaced with the same volume withdrawn at each time point. 
5.3.5 Cell Growth Inhibition studies by MTT assay 
 The two cancer cell lines were seeded at a density of 3 x 103 cells per well in 96-well 
microtiter culture plates. After overnight incubation, the medium was removed and replaced with 
a fresh medium containing vehicle control or indicated concentrations of drug. After appropriate 
incubation (as indicated in the results), 25ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution (5mg/ml in phosphate-buffered saline, PBS) was 
added to each well and incubated further for 2 h at 37°C. Upon termination, the supernatant was 
aspirated and the MTT formazan, formed by metabolically viable cells, was dissolved in DMSO 
(100ml). The plates were mixed for 30 min on a gyratory shaker, and the absorbance was 
measured at 595 nm on Ultra Multifunctional Microplate Reader (TECAN, Durham, NC). Each 
treatment had eight replicate wells and the mean values are reported. 
5.3.6 Cell fixing for confocal microscopy imaging of the cancer cells 
MDA-MB-231 and BxPC-3 cells (5 x 105) were seeded on collagen-coated cover-slips placed 
inside 100 mm cell culture dishes. The cells were allowed to attach overnight and the FITC 
conjugated PLGA nanoparticles were added to the cell cultures the next day at working 
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concentrations of 25 nM, 250 nM and 2.5 μM diluted directly from a 1 mM stock preparation. 
The incubation with formulations was done for 24 hours. Cover-slips with attached cells were 
washed twice with warm PBS at the end of incubation time, followed by fixing in 3.7% 
formaldehyde in PBS for 10 minutes at room temperature. This was followed by two more PBS 
washes and extraction with 0.1% Triton X-100 in PBS for 5 minutes. Cells were again washed 
twice with PBS before staining with fluorescent phallotoxin (Invitrogen). For staining, 5 μl 
methanolic stock of commercial phallotoxin was diluted into 200 μl PBS for each individual 
cover-slip. Staining was allowed to proceed at room temperature for 20 minutes before washing 
with PBS two more times. A drop of DAPI was placed on the cover-slips before they were 
mounted on slides for confocal observations. The confocal imaging was carried out on a Leica 
TCS SP5 confocal microscope with an inverted lens. 
5.4 Results and discussion 
 Nanoparticles encapsulating curcumin were fabricated with three different loading 
capacities: 24% (F1), 33% (F2), and 38% (F3) w/w. The size and zeta potential of the 
nanoparticle formulations is shown in table 9. The nanoparticle size for all three formulations 
was below 500 nm, a size well suited for intracellular uptake. The zeta potential was positive for 
all formulations and ranged from 1.9 to 7.5 mV. The release profile of the three nanoparticle 
formulations is represented in figure 31. Of the three nanoparticle formulations, the formulation 
F2 had the fastest rate and highest amount of drug release. Therefore, this formulation was 
chosen to test its antiproliferative activity on two cancer cell lines: MDA-MB-231 (Breast 
cancer) and BxPC3 (Pancreatic cancer). From here on, the CDF-loaded nanoparticle formulation 
F2 will be referred to as CDFNP.  
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 The cell growth inhibition studies show a time dependent and dose dependent effect of 
the formulation on both the cell lines.  
5.4.1 Cell growth inhibition of BxPC3 cells 
 The antiproliferative effect of free CDF, CDFNP, and empty PLGA nanoparticles on 
BxPC3 cells was evaluated at the end of 24, 48, and 120 hours of incubation. The IC50 values 
for each of the formulations are represented in table 10. 
 Figure 32A shows the cell proliferation profile of BxPC3 cells incubated for 24 hours 
with several concentrations of PLGA (nanoparticle control), CDF, CDFNP respectively. The 
blank PLGA nanoparticles have little to no toxicity on the cells at this time point. The CDF and 
CDFNP show a similar antiproliferative effect at all concentrations used. There is a 
concentration dependant antiproliferative effect displayed by both the free CDF and CDFNP. 
The activity of the free CDF and CDFNP after 48 hours of incubation is represented in 
figure 32B. At this time point, at CDF concentrations of 0.15 µM and higher, the 
antiproliferative effect of both the CDF and CDFNP increased significantly as compared to that 
at 24 hours. The IC50 for free CDF was 0.53 µM and that for CDFNP was 0.74 µM. Though the 
IC50 for CDFNP is higher than that for free CDF, it is to be noted that only about 57% of the 
encapsulated drug is released from the nanoparticle formulation as per the in vitro release profile. 
Therefore, the cell growth inhibition resulting from the CDFNP is remarkable as it takes much 
less free drug to elicit a similar antiproliferative response in the cancer cells when the drug is 
encapsulated in nanoparticles. In other words the encapsulation of CDF in nanoparticles 
improves the efficiency of the antiproliferative ability of CDF.  
At the end of 5 days, the inhibitory activity of both the CDF and CDFNP was more 
pronounced wherein more than 90% of the cell population was killed at a CDF concentration of 
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0.5 µM and above. The IC50 for free CDF was 0.09 µM whereas for the PLGA encapsulated 
CDF it was 0.12 µM. It is noteworthy that for the free CDF, the growth inhibition after a 
concentration of 0.25 µM remains the same for all higher concentrations after that. However, for 
the nanoparticle encapsulated CDF, the cell killing effect keeps increasing up to the 
concentration of 2.5 µM in a concentration dependent manner. This highlights the importance 
and advantage of encapsulating the drug in nanoparticles where they release the drug over an 
extended period of time thereby resulting in better antiproliferative activity as compared to free 
drug, especially over extended periods of time. 
5.4.2 Cell growth inhibition of MDA-MB-231 cells 
 Similar cell growth inhibition studies as that on the BxPC3 cells were conducted on the 
breast cancer cells, MDA-MB-231. In general there was a concentration dependent increase in 
the antiproliferative activity observed wherein with a increase in the drug concentration there 
was an increase in the cell growth inhibitory activity. The IC50 values are displayed in table 11. 
The empty PLGA nanoparticles had insignificant to no effect on the cell proliferation at the 
tested time points. 
 When compared to the BxPC3 cells, the MDA-MB-231 cells have higher IC50 values at 
all concentrations for both the CDF and CDFNP. This indicates that the BxPC3 cells are more 
responsive to treatment with CDF as compared to the breast cancer cells. 
 Figure 33A shows the antiproliferative activity of CDF, CDFNP, and empty PLGA 
nanoparticles when incubated with MDA-MB-231 cells. The empty PLGA nanoparticles show 
no antiproliferative activity on these cancer cells. The free CDF shows a concentration dependent 
antiproliferative activity wherein with an increase in the drug concentration there is an increase 
in the antiproliferative activity. Similarly, the CDFNP shows concentration dependant 
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antiproliferative activity though after a concentration of 0.75 µM there is no significant increase 
in cell growth inhibition with an increase in concentration. One possible reason for this 
observation with the CDFNP could be that at this early time point there might not be a 
significant polymer degradation occurring due to which the drug release from nanoparticles 
might be similar. The IC50 for free CDF was 1.66 µM whereas for the CDFNP it was 0.87 µM. 
The fact that only 43% of the drug is released at this time point further highlights the improved 
potency of the drug when encapsulated in PLGA nanoparticles. Taking this into consideration 
the actual IC50 for the CDFNP will be less than 0.87 µM. In either case, at this time point the 
IC50 value for the CDFNP is much less as compared to free CDF. 
At the end of 48 hours, the antiproliferative activity of both the CDF and CDF 
encapsulated nanoparticles is further increased as can be seen from figure 33B. At this time 
point the IC50 for free CDF is 0.47 µM whereas for the CDFNP it is 0.74 µM. There is a 
concentration dependent and a time dependent antiproliferative effect of the free CDF and CDF 
loaded nanoparticles on the breast cancer cells. At this time point the IC50 values for CDF and 
CDFNP decrease as compared to that for 24 hours. 
The antiproliferative potential further increased upon incubation for 5 days. As shown in 
figure 33C, after a concentration of 0.25 µM there is no significant increase in the 
antiproliferative activity with the CDF, however for the CDFNP the antiproliferative effect 
increases with concentration all the way up to the highest concentration of 2.5 µM. This 
observation suggests that the drug when encapsulated in nanoparticles due to its release over 
time produces effective antiproliferative activity as compared to free CDF. In the case of free 
CDF, after the concentration of 0.25 µM, any higher amount of free drug did not improve the 
antiproliferative activity implying that higher drug amounts does not add to the improvement in 
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antiproliferative activity. However when encapsulated in nanoparticles, the same excess of drug 
results in a continued increase in antiproliferative activity. This highlights the advantage of drug 
encapsulation in nanoparticles with regards to its improvement in antiproliferative effect 
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 Figure 31. The cumulative release of CDF from PLGA nanoparticle formulations with 
three different loading capacities (n=3; mean±s.d.). 
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Figure 32. Cell proliferation profile of BxPC3 cells (pancreatic cancer cell line) upon 
incubation with PLGA nanoparticles, free CDF, and CDFNP at the end of (A) 24 hours (B) 48 
hours, and (C) 5 days (n=8; mean±s.d.). Empty PLGA nanoparticles (PLGA) were used as 
nanoparticle control to assess the toxicity of the carrier itself.  
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Figure 33. Cell proliferation profile of MDA-MB-231 cells (breast cancer cell line) upon 
incubation with PLGA nanoparticles, free CDF, and CDFNP at the end of (A) 24 hours (B) 48 
hours, and (C) 5 days (n=8; mean±s.d.). Empty PLGA nanoparticles (PLGA) were used as 
nanoparticle control to assess the toxicity of the carrier itself. 
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Figure 34. Confocal microscopy image of MDA-MB-231 cells after incubation with 
FITC conjugated PLGA nanoparticles (green fluorescence) for 24 hours. The cell nuclei were 
labeled with DAPI and the cytoskeleton of the cell was labeled red with Rhodamine-Phalloidin. 
The green fluorescence pertains to the FITC-conjugated PLGA nanoparticles.  
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Formulation Loading (%w/w) Size (nm) Zeta potential (mV) 
F1 24% 362.7±29.1 1.93±2.77 
F2 33% 283.3±13.2 7.45±2.09 
F3 38% 415.7±17.2 6.11±4.03 
 
Table 9. Size and zeta potential measurements of the nanoparticle formulations 
encapsulating CDF with different loading capacities. 
 
 
 
 
Table 10. IC50 values of CDF and CDF-loaded PLGA nanoparticles (CDFNP) against 
BxPC3 cells (pancreatic cancer). 
 
 
 
 
Table 11. IC50 values of CDF and CDF-loaded PLGA nanoparticles (CDFNP) against 
MDA-MB-231 cells (breast cancer). 
 
 
 
 
Time (h) IC50(µM) CDF CDFNP 
24  0.54 0.63 
48  0.53 0.74 
120  0.09 0.12 
Time (h) IC50 (µM) CDF CDFNP 
24  1.66 0.87 
48  0.47 0.74 
120  0.15 0.22 
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5.5 Conclusions 
 The novel curcumin analogue, CDF was encapsulated in PLGA nanoparticles with 
different loading capacities of 24%, 33%, and 38%. In vitro release studies were performed in 
which the formulation with 33% loading showed the fastest rate and the highest amount of drug 
release compared to the other formulations. This formulation was chosen to test its 
antiproliferative potential on BxPC3 cells (pancreatic cancer) and MDA-MB-231 cells (breast 
cancer). The pancreatic cancer cells were more sensitive to drug treatment as compared to the 
breast cancer cells. This is evident from the IC50 values of the free CDF and the CDFNP.  
 In both the cell lines there was a clear time- and concentration-dependent cell growth 
inhibition. In case of the BxPC3 cells, free CDF had a IC50 value less than that for the CDF 
encapsulated nanoparticles. However, it is to be noted that at the time points tested, only a part of 
the drug is released from the nanoparticles. Therefore, the cell killing that is observed is from the 
released drug and not the total amount that was encapsulated. With this fact taken into 
consideration, the actual IC50 value of the CDFNP is less than the calculated value from the cell 
proliferative index profile. The same holds true for the IC50 values of the CDFNP with respect to 
breast cancer cells. The free drug had shown a saturation antiproliferative effect where after a 
certain concentration there was no enhancement in the antiproliferative activity whereas with the 
CDFNP, there was a continual increase in the antiproliferative effect with an increase in 
concentration. This underscores the advantage of drug encapsulation in nanoparticles where the 
drug is released slowly over a period of time, thereby increasing the antiproliferative potential of 
the drug in this case. Furthermore, the confocal microscopy images of the FITC labeled PLGA 
nanoparticles incubated with MDA-MB-231 cells show the nanoparticles present in the cells 
(figure 34). This suggests that the CDFNP are likely being internalized by the cells thereby 
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resulting in improved antiproliferative efficiency by way of releasing the drug intracellularly 
though some drug may be released extracellularly. Taken together, the data from this work 
clearly emphasizes the advantage of nanoparticle encapsulated drug delivery of CDF to improve 
the potency and efficiency of the drug reflected by its antiproliferative activity. Based on the 
excellent activity of CDF in the cancer cell lines, a future goal of the lab is to encapsulate CDF 
plus doxorubicin and study the degradation and pharmacokinetics for development of this 
formulation for application in an in vivo model of metastatic breast cancer by pulmonary 
administration. 
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
It is well established in the literature that the lungs are permeable to proteins and small 
molecules, however, few studies systematically investigate the pulmonary biodistribution of 
nanoparticles from a drug delivery standpoint. The first specific aim of my work focused on the 
extrapulmonary transit of polystyrene nanoparticles and their biodistribution throughout the 
body, following administration to the lungs via pharyngeal aspiration. This research has 
uncovered the possible potential of nanoparticle-based pulmonary drug delivery systems for 
several important therapeutic applications.  From these studies, it is evident that nanoparticle 
translocation out of the lungs occurs in a size dependent and a time dependent manner. 
Interesting kinetics are observed, wherein large size (900 nm) nanoparticles have a higher total 
uptake at the early time point of 1 hour whereas the 50 nm size nanoparticles had the highest 
total uptake at 5 hours. Biodistribution studies demonstrate that a greater percentage of 
nanoparticles deposit in the lymph nodes surrounding the neck and thoracic region, however 
some deposition is also observed in the spleen and heart. Lymph node deposition was also found 
to occur in a size dependent manner, wherein the smallest nanoparticles deposited in larger 
amounts at the end of 5 hours as compared to the larger sized nanoparticles.  This finding is of 
great interest due to the role lymph nodes are known to play in generation of immune response. 
Therefore, the observation of nanoparticle transit to lymph nodes might be of potential interest 
for effectively administering vaccine based therapies. Additionally, axillary lymph nodes 
(involved in metastatic spread of breast cancers) were found to have the highest nanoparticle 
deposition compared to all lymph nodes investigated. Therefore, pulmonary delivery of 
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nanoparticle-based anti-cancer drugs may serve as an effective alternative in the treatment of 
metastatic breast cancers with nodal involvement.  
Though this study has highlighted the extrapulmonary biodistribution potential of 
nanoparticles after administration to the lungs. The study would be far from complete with 
regards to a translational perspective without studies looking at the tissue degradation of 
polymeric nanoparticle systems. Moreover, in this study, polystyrene nanoparticles were used to 
investigate nanoparticle translocation from the lungs. However, for purposes of drug delivery, a 
biodegradable nanocarrier system is desired. For this purpose, PLGA is one of the most widely 
used biodegradable polymers for drug delivery applications. The degradation of PLGA plays an 
important role in the release of drug from the nanoparticle system. Therefore, knowledge of the 
in vivo tissue degradation characteristics of PLGA nanoparticles is necessary in order to design 
effective drug delivery systems with predictable drug release properties. Therefore, my second 
specific aim was to investigate the in vivo tissue degradation and distribution of 200 nm and 500 
nm PLGA nanoparticles. The in vitro degradation of the PLGA nanoparticles suggests that it 
follows a first order degradation pattern as observed from the data fit with good regression 
coefficient (>0.9) in the equation for first order degradation. Interestingly, the degradation in vivo 
in the liver and spleen also reflected a first order process. However, differences were observed in 
the rate of degradation in vivo as compared to that in vitro in liver and spleen for 200 nm and in 
spleen for 500 nm nanoparticles. Additionally, this research revealed differences in nanoparticle 
degradation among the tissues (liver and spleen) for each size apart from giving information 
about the degradation in tissues over time. Knowledge of the rate and extent of polymer 
degradation in tissues has significant implications in the design of polymer based drug delivery 
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systems, as it provides a quantitative means indicative of a predictable drug release thereby 
resulting in improvement of treatment efficacy.  
CDF encapsulated PLGA nanoparticles (CDFNP) were formulated and tested for their 
activity in two cancer cell lines which formed the specific aim 3. CDF when encapsulated into 
PLGA nanoparticles has shown better activity as compared to free CDF in both the cell lines. 
The activity of CDF encapsulated PLGA nanoparticles results from only part of the encapsulated 
drug that is being released at the specific time points. Taking this into consideration, the results 
suggest that encapsulation of CDF into PLGA nanoparticles improves the activity of the drug 
considerably. Based on the effectiveness of CDFNP, it would be worthwhile to co-encapsulate 
CDF and doxorubicin into PLGA nanoparticles for improved anticancer activity. Therefore, 
results from the third specific aim set the stage for the development of PLGA nanoparticles 
encapsulating CDF and doxorubicin as a combination treatment in an in vivo model of metastatic 
breast cancer. 
On the whole, our work investigating the extrapulmonary transit of nanoparticles has 
significant implications in several clinically relevant pathologic conditions such as breast cancer 
with nodal involvement (specifically ALN), lymph node related disorders and in vaccine 
delivery. This body of work provides a platform for investigating a new approach in the 
treatment of metastatic breast cancer achieved by targeted lymph node delivery of the active 
agent post pulmonary administration. Specifically, results from this work will be used in the 
future to investigate the pulmonary administration of PLGA nanoparticles encapsulating CDF 
and doxorubicin in an animal model of metastatic breast cancer.  
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Finally, based on knowledge gained from all my work, I hope that an effective drug 
delivery system can be designed in order to achieve lymph node deposition and subsequent 
cytotoxic and immunomodulatory effect following administration from the lungs. I believe that 
this work has provided a possible new insight into metastatic breast cancer therapy in addition to 
providing a platform for a robust and calculated design of polymeric nanoparticle delivery 
systems intended to achieve the desired and pre-determined performance characteristics from a 
therapeutic standpoint. 
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 The lungs are an attractive route for drug delivery due to their high epithelial surface area 
available for absorption, a thin epithelium and extensive vasculature to name a few. Accordingly, 
a vast number of small molecule drugs, peptides, and proteins have been used to investigate their 
translocation across the lungs with many of the tested candidates showing excellent 
pharmacokinetics following pulmonary administration.  Findings from all these studies over the 
years have strongly established the lungs as a route for drug delivery of small molecules and 
proteins. Nanoparticles on the other hand have gained increasing interest in drug delivery due to 
the wide variety of advantages they possess that allow for temporal, spatial and targeted delivery 
of therapeutics that can be fine tuned for various applications. Further, the pulmonary 
administration of polymeric nanoparticle based drug delivery systems is of great interest for both 
systemic and localized therapies. However, little is understood about the relationship between 
nanoparticle size and its effect on pulmonary absorption from a drug delivery perspective. 
Therefore the aim of this study was to investigate the effect of nanoparticle size on their 
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biodistribution from lungs after pulmonary administration with a special emphasis on their 
lymph node distribution. Interesting observations were made wherein polystyrene nanoparticles 
demonstrated significant translocation out of the lungs into extrapulmonary organs. 
Nanoparticles predominantly deposited in the regional lymph nodes surrounding the lungs as 
compared to that in other tissues. Furthermore, lymph node deposition of nanoparticles occurred 
in a time dependent and size dependent manner. The smallest size nanoparticles (50 nm) 
demonstrated the highest lymph node deposition among all sizes tested and increased with time. 
Results from this study suggest that nanoparticles may potentially be employed in the treatment 
of lymph related diseases following pulmonary administration. 
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